

1 **Untargeted proteomics enables ultra-rapid variant prioritization in mitochondrial** 2 **and other rare diseases**

3
4 Daniella H. Hock^{1,2,3,*}, Nikeisha J. Caruana^{1,4}, Liana N. Semcesen¹, Nicole J. Lake⁵, Luke
5 E. Formosa⁶, Sumudu S. C. Amarasekera², Tegan Stait², Simone Tregoning², Leah E.
6 Frajman², David R. L. Robinson¹, Megan Ball^{2,10,12}, Boris Reljic^{1,6}, Bryony Ryder⁷, Mathew
7 J. Wallis^{8,9}, Anand Vasudevan¹⁰, Cara Beck³, Heidi Peters^{11,12}, Joy Lee^{3,11}, MitoMDT
8 Diagnostic Network for Genomics and Omics^{**}, Vasiliki Karlaftis^{2,12}, Chantal Attard^{2,12},
9 Paul Monagle^{2,12,13,14}, Amanda Samarasinghe², Rosie Brown^{2,3}, Weimin Bi^{15,16}, Monkol
10 Lek⁵, Robert McFarland^{17,18}, Robert W. Taylor^{17,18}, Michael T. Ryan⁶, Zornitza Stark^{2,3,12},
11 John Christodoulou^{2,3,12}, Alison G. Compton^{2,3,12}, David R. Thorburn^{2,3,12*}, David A.
12 Stroud^{1,2,3*}

13 14 Affiliations

15 ¹Department of Biochemistry and Pharmacology, Bio21 Molecular Science and
16 Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia

17 ²Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia

18 ³Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne,
19 VIC, 3052, Australia

20 ⁴Institute for Health and Sport (iHeS), Victoria University, Melbourne, VIC, 3011, Australia

21 ⁵Department of Genetics, Yale School of Medicine, New Haven, CT 06510 USA

22 ⁶Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery
23 Institute, Monash University, 3800, Melbourne, Australia

24 ⁷Paediatric and Adult National Metabolic Service, Te Toka Tumai, Te Whatu Ora Health
25 New Zealand, Auckland, New Zealand

26 ⁸Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS 7001,
27 Australia

28 ⁹School of Medicine and Menzies institute for Medical Research, University of Tasmania,
29 Hobart, TAS 7001, Australia

30 ¹⁰Royal Women's Hospital, Melbourne, VIC, 3052, Australia

31 ¹¹Department of Metabolic Medicine, Royal Children's Hospital, Melbourne, VIC 3052,
32 Australia

33 ¹²Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia

34 ¹³Department of Haematology, Royal Children's Hospital, Parkville VIC, Australia

35 ¹⁴Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia

36 ¹⁵Department of Molecular and Human Genetics, Baylor College of Medicine, Houston,
37 TX, 77030, USA.

38 ¹⁶Baylor Genetics, Houston, TX, 77021, USA.

39 ¹⁷Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of
40 Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, United
41 Kingdom

42 ¹⁸NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon
43 Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK

44

45 *To whom correspondence should be addressed. Tel: +61-3-8344-8317 Email:
46 daniella.hock@unimelb.edu.au (Daniella H. Hock) Tel: +61-3-8341-6235 Email:
47 david.thorburn@mcri.edu.au (David R. Thorburn); Tel: +61-3-8344-7316; Email:
48 david.stroud@unimelb.edu.au (David A. Stroud).

49

50 **MitoMDT Diagnostic Network for Genomics and Omics members are listed at the end
51 of the manuscript.

52

53 **Abstract**

54 Only half of individuals with suspected rare diseases receive a definitive genetic diagnosis
55 following genomic testing. A genetic diagnosis allows access to appropriate patient care
56 and reduces the number of potentially unnecessary interventions and related healthcare
57 costs. Here, we demonstrate that an untargeted quantitative mass-spectrometry
58 approach quantifying >6,000 proteins in primary fibroblasts representing >80% of known
59 mitochondrial disease genes can provide functional evidence for 88% of individuals in a
60 cohort of known primary mitochondrial diseases. We profiled >90 individuals, including
61 28 with confirmed disease and diagnosed 6 individuals with variants in both nuclear and
62 mitochondrial genes. Lastly, we developed an ultra-rapid proteomics pipeline using
63 minimally invasive peripheral blood mononuclear cells to support upgrade of variant
64 pathogenicity in as little as 54 hours in critically ill infants with suspected mitochondrial
65 disorders. This study supports the integration of a single untargeted proteomics test into
66 routine diagnostic practice for the diagnosis of rare genetic disorders in clinically
67 actionable timelines, offering a paradigm shift for the functional validation of genetic
68 variants.

69

70 **Introduction**

71 Despite advances in genomic sequencing approaches, only 35-70% of individuals with
72 suspected rare disease receive a molecular diagnosis following whole exome sequencing
73 (WES) or whole genome sequencing (WGS)¹⁻⁵. Negative cases generally remain
74 undiagnosed due to variants being refractory to short-read sequencing approaches or
75 when detected variants of uncertain significance (VUS, Class 3) are detected, requiring
76 functional evidence to be upgraded to likely pathogenic (Class 4) or pathogenic (Class 5).
77 Mitochondrial disease is an umbrella term for a group of over 300 rare monogenic
78 disorders affecting mitochondrial energy production in the form of ATP⁶. These disorders
79 can arise from sporadic or inherited variants in either nuclear or mitochondrial DNA
80 (mtDNA), presenting at any stage of life with a myriad of symptoms affecting either a
81 single organ or in a multisystemic manner⁷. Mitochondrial diseases affect approximately
82 1 in 5,000 live births⁸ with limited treatments available, reinforcing the importance of a
83 genomic diagnosis for early intervention in affected individuals. A genomic diagnosis also
84 facilitates informed reproductive options such as prenatal diagnosis (PND) and assisted
85 reproductive technologies such as preimplantation genetic testing (PGT) and
86 mitochondrial replacement therapy (MRT)⁹.

87 Functional approaches to assess VUS pathogenicity in mitochondrial disease have
88 historically relied on targeted and low throughput tests such as respiratory chain
89 enzymology (RCE), SDS-polyacrylamide gel electrophoresis (PAGE) or Blue Native (BN)-
90 PAGE and immunoblotting. RCE assesses the activity of the mitochondrial respiratory
91 chain complexes I-IV and is typically normalised to the activity of a single enzyme, citrate
92 synthase (CS), to account for variability in mitochondrial content determined by sample
93 quality, amount and storage¹⁰. Western blotting has also been used for the confirmation
94 of VUS pathogenicity based on protein abundance or differential size, although it relies
95 on having a strong genetic lead for disease causation from genomic data and the
96 commercial availability of antibodies for the desired protein.

97 Other non-targeted functional approaches such as transcriptomics and proteomics have
98 also been applied to the diagnosis of mitochondrial diseases. In selected cohorts,
99 transcriptomics has been shown to increase the diagnosis of mitochondrial disorders by
100 10-16%^{11, 12} and other rare Mendelian disorders by 7-17%¹³⁻¹⁵. Although transcriptomic

101 analysis can be a powerful tool in assessing pathogenicity of intronic and splice variants,
102 this approach has limited power in offering functional information on missense variants,
103 one of the most common and challenging classes of variants to assess^{16, 17}. Splice
104 variants are predicted to account for only 10% of pathogenic variants associated with
105 autosomal recessive disorders¹⁸, in line with current diagnostic rates achieved by
106 transcriptomics. Missense variants, on the other hand, account for 60% of pathogenic
107 variants¹⁸ and approximately 40% of them are expected to result in reduced protein levels
108 due to protein instability and turnover¹⁹. Proteomics can detect such changes and has
109 been demonstrated to contribute to the diagnosis of Mendelian disorders by providing
110 functional evidence for not only missense variants but also splice, deep intronic and copy
111 number variants^{11, 20-25}. Despite this, there is a lack of data to inform the general utility of
112 proteomics in rare disease diagnoses as an untargeted approach like genomics and
113 transcriptomics.

114 Here, we present a systematic analysis demonstrating the utility of proteomics in the
115 detection of rare mitochondrial disorders and provide the first validated pipeline for ultra-
116 rapid functional testing using peripheral blood mononuclear cells (PBMCs). Reference
117 proteomics data and associated bioinformatics tools for performing the proteome analysis
118 approaches developed for these investigations can be applied to user-uploaded data
119 through our interactive web tool (<https://rdmassspec.shinyapps.io/RDMSExplorer/>).

120

121 **Results**


122 To validate our untargeted proteomic approach in the detection of mitochondrial disorders,
123 we first analysed primary fibroblast cell lines from a cohort of 24 patients with confirmed
124 genetic diagnoses based on known pathogenic or likely pathogenic nuclear or mtDNA-
125 encoded variants. This validation cohort (VC) included cell lines with defects in subunits
126 or assembly factors for each of the five individual OXPHOS complexes as well as defects
127 of mtDNA translation that impact multiple complexes, causing a combined OXPHOS
128 biochemical defect (**Fig 1A, Supplementary Table 1**). Principal component analysis
129 showed that proteomes segregate according to their primary defect (**Fig. 1B**) and
130 hierarchical clustering of OXPHOS subunits and assembly factors identified clear profiles
131 (**Supplementary Fig. 1A, B**). We have previously shown similar profiles to be present in

132 gene-edited HEK293T knockout of Complex I subunits²⁶. Comparison of mitochondrial
133 proteomes from our validation cohort of fibroblast cell lines and corresponding gene-
134 edited HEK293T knockout cell lines (knockout cohort, KC) showed good correlation of
135 dysregulated proteins (**Supplementary Fig. 2A, B**).

136
137 The maximum theoretical coverage of known mitochondrial disease gene products from
138 the fractionated library was 80%, with a routine coverage of 64% in a standard 95-minute
139 library-supported DIA run from fibroblast samples (**Fig. 1C**). Our approach could also
140 detect proteins corresponding to 37% of the Mendeliome (i.e., encoded by known disease
141 genes) in a standard 95-minute run, supporting the potential utility of proteomics as a
142 disease agnostic test in the resolution of many rare monogenic disorders. In terms of
143 variant type in the validation cohort, the most common type was nuclear single nucleotide
144 variants (48%) followed by mtDNA single nucleotide variants (16%), indel (16%), splice
145 site (13%) and deep intronic (6%) (**Fig. 1D**). We quantified the abundance of the protein
146 of interest in 67% of our investigations with the most common outcome being the protein
147 abundance readily quantified in controls and absent in proband (42%) followed by a
148 decrease in the patient relative to controls (21%) (**Fig. 1E**). In 29% of cases the protein
149 of interest was not detected in either proband or control fibroblasts. For the cases where
150 the protein was identified in both proband and control fibroblasts, analysis of the standard
151 deviation show that ND1 abundance in VC6 (*MT-ND1*) was 97% relative to control median
152 and within the control distribution, while ND5 abundance in VC12 (*MT-ND5*) was 118%
153 relative to control median and approximately 3 standard deviations above the control
154 median (**Fig. 1F**). Other identified proteins were outside the control range and >9 standard
155 deviations below control median (**Fig. 1F**).

156

157



158

159 **Figure 1. Study design and validation cohort analysis** A – Quantitative proteomics experimental design
 160 overview. A fibroblast validation cohort (VC), HEK293T knockout cohort (KC), undiagnosed patient cohort
 161 (UDP) and supporting cohort (SC) prepared using S-Trap™ columns. Digested peptides were subjected to
 162 Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) Data Independent Acquisition (DIA).
 163 Pooled control peptides were fractionated using strong cation-exchange (SCX) chromatography and data
 164 acquired as Data Dependent Acquisition (DDA) to generate spectral libraries for fibroblasts (Fbs), HEK293T
 165 (HEK) and PBMcs. Raw data were searched using Spectronaut® software and data analyses were
 166 performed with a combination of Perseus software, Python and R. **B** – Principal Component Analysis (PCA)
 167 of the fibroblast validation cohort (N=24) relative to controls based on the differential abundance of whole
 168 cell proteins calculated from t-test. **C** – Venn diagram showing the coverage of Mendeliome (v. 0.12869,
 169 top panel) and Mitochondrial disease (v. 0.787, bottom panel) lists including green (diagnostic-grade) and
 170 amber (borderline diagnostic-grade) genes retrieved from PanelApp Australia²⁷. **D** – Summary of the
 171 genetic variant types analysed in the validation cohort (VC). **E** – Summary of the findings in the VC based
 172 on protein identification and abundance. In 42% (10/24) of the cases the protein expected to be affected by
 173 the genetic variant is not detected in the patient while it is detected in the controls. In 29% (7/24) of the
 174 cases, the protein is not detected via quantitative proteomics, in 21% (5/24) of the cases, the protein is
 175 decreased in abundance in the patient compared to the 5 controls, and in 4% (1/24) of the cases, the protein

176 is increased compared to the controls analysed. SNV = single nucleotide variant. **F** – Protein standard
177 deviation from control median of the respective affected gene in controls (purple) and probands (red) in the
178 validation cohort (VC). Standard deviation was calculated from the median control variance.

179
180 Mitochondrial content has previously been calculated in proteomics data using the mean
181 abundance of experimentally validated mitochondrial proteins in the MitoCarta 3.0
182 database^{28, 29}. We noticed that the mean abundance of mitochondrial proteins as a group
183 varied between cell lines in our validation cohort (**Supplementary Fig. 3A**) but not control
184 individuals (**Supplementary Fig. 3B**). This phenomenon is typically taken into
185 consideration in enzymology analyses by expressing enzyme rates as citrate synthase
186 (CS) ratios to account for mitochondrial proliferation or cell/tissue variability^{10, 30}. CS
187 enzyme activity in our validation cohort varied greatly (**Supplementary Fig. 3A, upper**
188 **panel**), consistent with altered mitochondrial content. Surprisingly, while CS activity did
189 have a weak positive correlation with the relative abundance of CS protein as detected
190 by proteomics (**Supplementary Fig. 3C, left panel**), it did not correlate with mitochondrial
191 content calculated from the abundance of mitochondrial proteins (**Supplementary Fig.**
192 **3C, middle panel**). In line with this, CS protein abundance also did not correlate with
193 mitochondrial content calculated from proteomics data (**Supplementary Fig. 3C, right**
194 **panel**). Since the nature of proteomics-based RCA is relative protein abundance, we
195 concluded that mean mitochondrial protein abundance is the appropriate metric to
196 normalise proteomics data. We built a differential mitochondrial abundance correction
197 step into our RCA calculations (see **Materials and Methods** for detailed information).
198 This correction is of benefit for cell lines that may have different mitochondrial content to
199 controls and corrects for mitochondrial content before calculating the relative abundance
200 of each complex.

201
202 We next sought to systematically benchmark our RCA analysis against clinical RCE. RCE
203 was performed on 23 of the 24 fibroblast lines in the validation cohort, and was also
204 performed on skeletal muscle (SKM) or lymphoblastoid cell lines (LCLs) for 17 of the 24
205 patients. Results are presented relative to CS (**Supplementary Table 2**) and the Bernier
206 criteria³¹ were used to classify results. Fibroblast RCE detected a definite defect (<30%,
207 major criterion) in the expected complex(es) for 19 of 24 fibroblast lines (79%) while three

208 [VC4 (*NDUFS2*), VC7 (*NDUFAF1*) and VC10 (*NDUFB10*)] had a probable defect (minor
209 criterion) and RCE did not detect a defect in VC19 (*COX6B1*) fibroblasts (**Fig. 2A left**
210 **panel, Supplementary Table 2**). When skeletal muscle or LCLs were also available,
211 RCE revealed a major defect in 9 of 17 of the analyses (53%), and a minor defect in four
212 (23%) while three were not deficient (18%) and one was not available (6%)(**Fig. 2A, right**
213 **panel**).

214
215 Relative complex abundance (RCA) analysis was performed incorporating the correction
216 for mitochondrial content (**Supplementary Fig. 4**) as described above. We classified a
217 major defect as an RCA abundance $\leq 65\%$ relative to controls or $\leq 75\%$ with absent
218 detection of the protein of interest in the proband with >2 peptides detected in controls
219 while minor defects were classified by an RCA abundance of $\leq 75\%$ relative to controls
220 (**Supplementary Table 2**). Using these criteria, a major RCA defect was detected in 88%
221 of the cell lines in the validation cohort, a minor defect in a single case, VC19 (*COX6B1*),
222 and no defect was detected in three cell lines with mtDNA variants (**Fig. 2B**). Overall,
223 there is no strong correlation between RCE activity and an RCA value relative to control
224 ($R=0.072$, $p=0.78$) (**Fig. 2C**).


225
226 For isolated Complex I disorders, 83% (10/12 patients) had a complex I abundance lower
227 than 75% relative to controls analysed ($p<0.0001$). Two of the three Complex I-deficient
228 fibroblast lines harbouring missense mtDNA-encoded variants were refractory to RCA
229 analysis but diagnostic by RCE. mtDNA variant heteroplasmy in fibroblasts was 92% for
230 VC6 *MT-ND1* and 71% for VC12 *MT-ND5*, highlighting a limitation of our approach in the
231 detection of some mtDNA-driven disorders. Importantly, in all 10 fibroblast lines where
232 RCA was diagnostic for a Complex I disorder, lower abundance ($<65\%$ relative to
233 controls) of Complexes III, IV and V were not noted (**Supplementary Fig. 4**). While
234 Complex II was reduced to $<75\%$ in four of these, RCE similarly identified a probable
235 Complex II defect for one (*FOXRED1*), supporting the accuracy and specificity of RCA
236 analysis. In 7/7 individuals with isolated Complex II, III or IV disorders, the abundance of
237 the relevant complex was reduced to $<75\%$ controls (**Fig. 2D**) however t-test significance
238 varied, especially in CII and IV defects where the number of detected subunits was as

239 low as two. All were specific for the relevant isolated defect except for *UQCRC2* where a
240 Complex I abundance of 67% control ($p < 0.0001$) was noted, as expected for Complex III
241 disorders³².

242

243 For isolated disorders involving Complexes I-IV due to nuclear defects, we determine an
244 RCA value in fibroblasts of <65% controls to be diagnostic. The same threshold may also
245 be applied to isolated disorders caused by pathogenic variants in mtDNA including those
246 leading to Complex V deficiency, however smaller reductions may not exclude
247 pathogenicity as seen in VC6 (*MT-ND1*), VC12 (*MT-ND5*) and VC20 (*MT-ATP6*) (**Fig.**
248 **2D**). Interestingly, in the case of VC6 this was likely not due to heteroplasmy, which was
249 92% NC_012920.1(*MT-ND1*):m.3949C>T in fibroblasts. On the other hand, in VC12 the
250 NC_012920.1(*MT-ND5*):m.13513G>A variant found at 71% in fibroblasts, did not show
251 the expected RCA defect while it satisfied the major criteria in RCE (**Supplementary**
252 **Table 2**), suggesting impaired enzyme kinetics in the absence of a structural Complex I
253 defect. Finally, we found that defects directly impacting mitochondrial translation such as
254 *MRPS34* fibroblasts presenting with a destabilised mitochondrial ribosome small
255 subunit²⁵, *MT-TK* which encodes the mitochondrial lysine transfer RNA³³, *MTFMT* which
256 encodes the mitochondrial methionyl-tRNA formyltransferase³⁴, and *FARS2* encoding
257 mitochondrial phenylalanyl-tRNA synthetase, led to combined Complex I and IV defects
258 that each met criteria of an RCA value <65% control (**Fig. 2D**), consistent with the major
259 criterion observed in RCE (**Supplementary Table 2**). Taken together, fibroblast RCA
260 detected an OXPHOS defect at <65% relative to controls in the expected complex(es) for
261 20 of 24 fibroblast lines tested (88%) (**Fig. 2B**). One fibroblast line, VC19 (*COX6B1*), had
262 an RCA of 71% for Complex IV relative to controls, which is in line with a previous report
263 showing remaining assembled complex³⁵ and the peripheral position of the late
264 assembled COX6B1 subunit in the structure of Complex IV^{36, 37}. Three fibroblast lines
265 where a definitive defect was not observed by RCA harboured variants in mtDNA,
266 suggesting that this class of variant may be more refractory to RCA analysis. Despite this,
267 proteomics-based RCA outperformed RCE in the detection of primary mitochondrial
268 disease. It is important to note here that the nature of proteomics as an untargeted
269 approach means that additional analyses can be performed from the same proteomic

270 data, such as reduced abundance of specific proteins encoded by the gene of interest
 271 (**Fig. 1E, F**) and co-dependent proteins in structural modules (**Supplementary Fig. 1B**).
 272 This is exemplified in the VC2 (*NDUFS6*) case where despite showing a Complex I
 273 abundance of 74%, topographical mapping of Complex I subunit abundances against the
 274 cryo-EM structure show specific reduction of the N-module of Complex I, providing strong
 275 evidence in supporting disease causation.



276
 277 **Figure 2. Proteomics outperforms clinical respiratory chain enzymology in detection of**
 278 **mitochondrial disorders** **A** – (left) Summary of the RCE results in fibroblasts according to the Bernier
 279 criteria³¹. (right) Summary of the RCE results in tissues (skeletal muscle, skm or lymphoblastoid cell line,
 280 LCL) according to the Bernier criteria³¹. **B** – Summary of the RCA results from quantitative proteomic data.
 281 **C** – Pearson correlation between RCA results and Respiratory Chain Enzymology results for Complexes I,
 282 III and IV. **D** – RCA results of OXPHOS complexes from the validation cohort showing the predicted affected
 283 complexes for each cell line. CI-V = Complex I-V. Tr. = translation. Middle bar represents mean complex
 284 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a
 285 paired t-test between the individual protein means. **** = $p < 0.0001$, *** = $p < 0.001$, ** = $p < 0.01$, * = $p < 0.05$,
 286 ns = not significant, $p > 0.05$.

287

288 After benchmarking quantitative proteomics and RCA analysis against the validation
289 cohort, we applied our label-free DIA method to six undiagnosed cases where primary
290 fibroblast or skeletal muscle were available for proteomic analysis.

291

292 **UDP1 (*MT-ATP6*)**


293 UDP1 (*MT-ATP6*) was a four-year-old child who had intrauterine growth retardation,
294 truncal hypotonia, microcephaly, global developmental delay, left ventricular
295 noncompaction and Wolff-Parkinson-White syndrome. Biochemically there was a
296 marginal elevation of blood lactate (2.8 mmol/L; normal range 0.7 – 2.0) and 3-
297 methylglutaconic aciduria. Missense variants were identified in *MT-ATP6*
298 [NC_012920.1(*MT-ATP6*):m.8672T>C;p.(Leu49Pro)], a *de novo* variant with 81%
299 heteroplasmy in blood, and *ATAD3A* (heterozygous c.683C>T;p.Thr228Met) from WES
300 plus mtDNA sequencing from blood and both classified as a VUS. Clinical RCE assays
301 typically do not include Complex V activity and proteomics was sought to provide
302 functional evidence. Despite proteomic RCA analysis showing no reduction in abundance
303 of Complex V (104% relative to controls), there was a reduction in the number of Complex
304 V subunits identified from 13 to 10 compared to the diagnosed *MT-ATP6* patient as well
305 as other cases in the same batch (**Fig. 3A** and **Supplementary Fig. 4**). The Complex V
306 subunits that are not detected in UDP1 (*MT-ATP6*) but are detected in VC20 (*MT-ATP6*)
307 are ATP5IF1, the ATPase inhibitor, and ATP5MD (ATP5MK/DAPIT) and ATP5MPL
308 (ATP5MJ/MP68/6.8PL), which like ATP6, are incorporated at a late stage in the assembly
309 of Complex V^{36, 38}. The latter suggests a specific turnover of late stage assembled
310 subunits of Complex V below the limit of detection of proteomics in the proband, which
311 contributes to the unchanged Complex V levels seen in the RCA of UDP1 (*MT-ATP6*).
312 We processed the same data using q-value sparse run-wise imputation in the
313 Spectronaut® that allows for peptides that were identified in one sample to be imputed at
314 the limit of detection in samples where they were not detected. This allowed us to estimate
315 the fold changes of ATP6 (*MT-ATP6*) and ATP5MPL proteins in UDP1 (*MT-ATP6*) and
316 correlate their reduced levels with VC20 (*MT-ATP6*) as well as confirming unchanged
317 levels of *ATAD3A* (**Fig. 3B**). Another data analysis strategy we explored for UDP1 (*MT-*
318 *ATP6*) was the use of an *in-silico* library-free analysis including the protein sequence of

319 the ATAD3A variant p.Thr228Met. As expected, the peptide containing the methionine at
320 position 228 was only detected in the patient (**Fig. 3C**) and present at ~43% of the
321 abundance relative to the canonical peptide expressed from the other allele
322 (**Supplementary Fig. 5A**). Taken together, these results suggest that the *MT-ATP6*
323 p.Leu49Pro variant is the likely diagnosis for this case.

324

325 The lack of a Complex V defect in proteomics RCA analysis of both *MT-ATP6* cases
326 (VC20 and UDP1) prompted us to analyse additional patients with known pathogenic
327 variants affecting Complex V. Supporting cohort probands SC1 and SC2 were two
328 unrelated infants presenting with lactic acidosis, cardiac abnormalities (persistent patent
329 ductus arteriosus, ventriculo-septal defect and cardiomyopathy), mild dysmorphic facial
330 features, hypospadias, hyperammonaemia and 3-methyl-glutaconic aciduria. Targeted
331 gene sequencing based on this phenotype identified in both individuals a homozygous
332 intronic founder variant NM_017866.6(*TMEM70*):c.317-2A>G classified as Class
333 5/pathogenic, with several patients previously reported³⁹⁻⁴³. Skeletal muscle samples
334 were available for both cases and compared against three unrelated individuals using the
335 library-free DIA approach. Whole muscle proteomic analyses showed reduction of several
336 Complex V subunits in SC1 and SC2 respectively (**Fig. 3D** and **E**). RCA analyses
337 quantified the relative abundance of Complex V at 19% and 20% (**Fig. 3F** and **G**),
338 demonstrating that defects in Complex V can be detected using RCA analysis. *TMEM70*
339 has also been implicated in Complex I assembly^{44, 45}, although no defects in Complex I
340 abundance were noted in these muscle samples.

341



342

343 **Figure 3. Proteomics supports the diagnosis of patients with suspected mitochondrial disorders. A**
344 – Relative Complex Abundance (RCA) of Complex V subunits in undiagnosed patient UDP1 (*MT-ATP6*)
345 and diagnosed VC20 (*MT-ATP6*) patient. Middle bar represents mean complex abundance. Upper and

346 lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the
347 individual protein means. ns = not significant, $p > 0.05$. **B** – Correlation between \log_2 fold-changes from
348 whole-cell proteins from run-wise imputed data between undiagnosed patient UDP1 (*MT-ATP6*) and
349 diagnosed patient VC20 (*MT-ATP6*) harbouring mutations in *MT-ATP6* and controls showing reduced
350 abundance in late assembly proteins, MT-ATP6 and ATP5MPL, for both patients. **C** – Spectral intensity of
351 the peptide containing the ATAD3A p.Thr228Met variant detected in the UDP1 patient but not in controls.
352 **D** – Volcano plot of whole cell proteins from SC1 (*TMEM70*) whole-cell skeletal muscle compared to controls
353 (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent ± 2 -fold-
354 change equivalent and horizontal lines represent significance p -value ≤ 0.05 equivalent from a two-sample
355 t-test. **E** – Volcano plot of whole cell proteins from SC2 (*TMEM70*) whole-cell skeletal muscle compared to
356 controls (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent
357 ± 2 -fold-change equivalent and horizontal lines represent significance p -value ≤ 0.05 equivalent from a two-
358 sample t-test. **F** – Relative Complex Abundance (RCA) of OXPHOS subunits in undiagnosed patient SC1
359 (*TMEM70*). Middle bar represents mean complex abundance. Upper and lower bars represent 95%
360 confidence interval. Significance was calculated from a paired t-test between the individual protein means.
361 **** = $p < 0.0001$, *** = $p < 0.001$, * = $p < 0.05$, ns = not significant, $p > 0.05$. **G** – Relative Complex Abundance
362 (RCA) of OXPHOS subunits in undiagnosed patient SC2 (*TMEM70*). Middle bar represents mean complex
363 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a
364 paired t-test between the individual protein means. **** = $p < 0.0001$, *** = $p < 0.001$, ** = $p < 0.01$, * = $p < 0.05$.
365 **H** – Volcano plot of whole cell proteins from UDP4 (*CCDC47*) fibroblasts compared to controls showing
366 reduced abundance of *CCDC47*. No significant changes to Complex V proteins (orange). Vertical lines
367 represent ± 2 -fold-change equivalent and horizontal lines represent significance p -value ≤ 0.05 equivalent
368 from a two-sample t-test. **I** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP4
369 (*CCDC47*) fibroblasts compared to controls. * = $p < 0.05$, ns = not significant, $p > 0.05$. **J** – Volcano plot of
370 whole cell proteins from UDP5 (*NDUFA10*) fibroblasts compared to controls showing reduced abundance
371 of *NDUFA10* and other structural subunits of Complex I. Vertical lines represent ± 2 -fold-change equivalent
372 and horizontal lines represent significance p -value ≤ 0.05 equivalent. Blue = Complex I subunits. **K** –
373 Relative Complex Abundance (RCA) of OXPHOS complexes from UDP5 (*NDUFA10*) fibroblasts compared
374 to controls (N=4) showing isolated Complex I defect. Middle bar represents mean complex abundance.
375 Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test
376 between the individual protein means. **** = $p < 0.0001$, * = $p < 0.05$, ns = not significant, $p > 0.05$. **L** –
377 *NDUFA10* and *HIBCH* protein abundance from two-sample t-test in SC3, a confirmed *HIBCH* proband and
378 UDP5 (*NDUFA10*) whole-cell fibroblasts compared to controls showing an approximate half reduction in
379 *HIBCH* levels in UDP5 (*NDUFA10*, *HIBCH* carrier) compared to SC3 and unchanged *NDUFA10* levels in
380 SC3. **M** – Timeline for the rapid proteomics from live fibroblast sample receipt to results for UDP5
381 (*NDUFA10*) case achieved in less than 5 business days.

382

383 **UDP4 (*CCDC47*)**

384 UDP4 (*CCDC47*) was born to consanguineous parents, presenting with intrauterine
385 growth restriction, severe failure to thrive, short stature, hypotonia, marked developmental
386 delay, mildly dysmorphic features, severe pruritus woolly hair and increased plasma bile
387 acids (224 $\mu\text{mol/L}$; normal range < 7), Ricketts and decreased mitochondrial CIII activity
388 in liver and muscle⁴⁶. WES performed on DNA extracted from fibroblasts and analysed
389 using a mitochondrial disease gene panel identified single heterozygous missense

390 variants NM_001358921.2(COQ2):c.460G>C; p.(Gly154Arg) and
391 NM_020312.4(COQ9):c.826C>T p.(Arg276Trp). Suspecting a compound oligogenic
392 mechanism impacting Coenzyme Q biosynthesis, RCA analysis was performed on
393 fibroblast cells. No abundance changes to COQ9 or respiratory chain complexes I-IV
394 were identified, although an abundance of 84% in Complex V was noted (**Fig. 3H** and **I**).
395 This reduction was regarded as not biologically significant as no rare variants in Complex
396 V related genes were flagged from sequencing data. Transcriptomic analysis performed
397 in RNA extracted from skeletal muscle showed a reduced abundance of *CCDC47*
398 transcript (**Supplementary Fig. 5B**). Re-analysis of proteomics data was sought to
399 provide functional evidence to support the transcriptomic findings, which confirmed a
400 reduction in the abundance of *CCDC47* in primary fibroblasts from imputed data (**Fig. 3H**).
401 Re-analysis of sequencing data identified a homozygous variant
402 NM_020198.3(*CCDC47*):c.431C>G;p.(Thr144Asn). SpliceAI predicted (δ score 0.964)
403 the activation of a donor-splice site five nucleotides upstream of this variant, and PCR
404 analysis of the muscle cDNA showed the presence of both the missense transcript and a
405 second shorter one, missing 121 bp from the 3' end of exon 4 resulting in a loss-of-
406 function type transcript p.(Val143Glyfs*15) (**Supplementary Fig. 5C**). This variant is not
407 observed in the gnomAD population database nor any clinical cases previously but is
408 predicted to be classified as likely pathogenic/Class 4, supported by the observed splicing
409 defect, as well as reduced abundance in *CCDC47* transcript and *CCDC47* protein levels.
410 *CCDC47* has been previously linked to Trichohepatoneurodevelopmental Syndrome⁴⁷
411 (MIM 618268) which presents an overlapping phenotype to *UDP4* (*CCDC47*). The
412 observed reduction in *CCDC47* transcripts due to incorrect splicing is in keeping with
413 previously reported patients, all of whom harbour loss-of-function variants^{47, 48}.

414

415 **UDP5 (NDUFA10)**


416 UDP5 presented with nystagmus, hypotonia, vomiting and weight loss at 20 weeks of age.
417 She had lactic acidosis, concentric left ventricular hypertrophy with 48% ejection fraction,
418 T2 hyperintense lesions in the substantia nigra and passed away at 24 weeks of age.
419 Targeted exome sequencing analysis flagged candidate variants
420 NM_004544.4(*NDUFA10*):c.914T>C; p.(Leu305Pro) homozygous VUS/Class 3,

421 NM_014362.4(*HIBCH*):c.891+1G>A, heterozygous likely pathogenic/Class 4 and
422 NM_018292.5(*QRSL1*):c.22G>C, p.(Glu8Gln) heterozygous VUS/Class 3. Fibroblast
423 proteomics detected *NDUFA10* and *HIBCH* below 2-fold-change (representing >50%
424 reduction) in the patient relative to controls (**Fig. 3J and Supplementary Figure 5D**).
425 *QRSL1* level was slightly increased but not significant, which led us to further investigate
426 *NDUFA10* and *HIBCH* leads. *NDUFA10* is a structural subunit of Complex I and additional
427 functional evidence for pathogenicity could be drawn from reduced abundance of other
428 Complex I subunits, with RCA analysis quantifying Complex I abundance at 43% in UDP5
429 (*NDUFA10*) compared to controls, meeting the criteria for a major defect (**Fig. 3K**). We
430 further assessed whether the levels of *HIBCH* protein were compatible with a carrier
431 (heterozygous) state by analyzing fibroblasts from an unrelated patient (SC3) diagnosed
432 with bi-allelic pathogenic variants: NM_014362.4(*HIBCH*):c.891+1G>A &
433 NM_014362.4(*HIBCH*):c.470G>A; p.(Arg157Gln). Proteomic results show that *HIBCH*
434 protein in SC3 (*HIBCH*) is almost two times less abundant than in UDP5 (*NDUFA10*) (**Fig.**
435 **3L, left panel**) while the levels of *NDUFA10* protein were unchanged in SC3 (*HIBCH*),
436 suggesting that a reduction in *NDUFA10* is not a secondary defect from a primary *HIBCH*
437 defect (**Fig. 3L right panel**). The lack of any decrease in Complex I in SC3 (*HIBCH*)
438 suggests that the phenotype in UDP5 (*NDUFA10*) is likely to have arisen from the
439 *NDUFA10* variant while the *HIBCH* variant is expressed as a carrier and further
440 investigation for a second missed variant in *HIBCH* was not undertaken. UDP5 was the
441 first child of non-consanguineous parents of Māori ethnicity. The mother was 6 weeks
442 pregnant with a second child at the time of analysis and the family sought prenatal genetic
443 testing (PGT). With this in mind, we prioritised sample processing and analysis, and were
444 able to return results in less than 4 days from receipt of fibroblasts (**Fig. 3M**) with the
445 results sufficient to support the upgrade of the *NDUFA10* variant c.914T>C;
446 p.(Leu305Pro) to likely pathogenic/Class 4. This facilitated PGT, which confirmed
447 absence of the *NDUFA10* variant, allowing continuation of the pregnancy and delivery of
448 a healthy child who, at the time of writing, is 15-months old.

449
450 The rapid turnaround time (TAT) in this case was only possible as fibroblasts from UDP5
451 were available for analysis at the time of proteomics testing. Establishing and culturing a

452 new fibroblast line typically takes up to ~2 months and requires a skin biopsy⁴⁹ which is
453 increasingly considered invasive and can potentially delay a diagnosis. We sought to
454 explore the feasibility of rapid proteomics-based testing for suspected mitochondrial
455 disorders using peripheral blood mononuclear cells (PBMCs), which can be readily
456 obtained from whole blood and have been used in various diagnostic functional testing
457 approaches previously. To test the applicability of PBMCs in proteomic testing we first
458 generated a fractionated spectral library and compared it against the fibroblast spectral
459 library and coverage of Mendeliome proteins (**Fig. 4A**). The PBMC library was generated
460 from peptides of 39 normal individuals aged 0-17 years of age and can be used to
461 confidently identify 8,016 gene products, including 52% of known Mendeliome genes²⁷.
462 In comparison, our fibroblast spectral library covers 8,305 genes and 55% of the
463 Mendeliome. We performed a Principal Component Analysis (PCA) of whole-cell proteins
464 in the 37 PBMC samples showing that over 99% of the proteins are tightly clustered at
465 the whole-cell level and over 97% at the mitochondrial level (**Fig. 4B**).

466
467 Next, we validated the use of PBMCs against fibroblasts by analysing both sample types
468 from a diagnosed patient with pathogenic variants in *MRPL50* (Twin 2 in ²¹, SC4 and
469 SC5). *MRPL50* is a structural subunit of the mitoribosome⁵⁰ and defects in this subunit
470 lead to impaired assembly of the large mitoribosomal subunit (mtLSU)²¹. We performed
471 a correlation of the log₂ fold-change levels of mitochondrial proteins identified in both
472 samples relative to controls which showed reduced abundance of multiple proteins
473 belonging to the mtLSU in both sample types (**Fig. 4C**). RCA quantified the abundance
474 of the mtLSU in 63% and 48% in PBMCs and fibroblasts respectively (**Supplementary**
475 **Fig. 5E**).



476
 477
 478
 479

Figure 4. Utility of ultra-rapid proteomics supports the diagnosis of critically ill infants with suspected mitochondrial disorders A – Venn diagram showing the coverage of Mendeliome genes (PanelApp Australia Green and Amber entries, 4,264 genes) in the fibroblast spectral library (55% of

480 Mendeliome list of genes) and PBMC library (52% of Mendeliome list of genes). **B** – Principal Component
481 Analysis (PCA) of the pilot PBMC normative data (N=37) for whole-cell proteins (top panel) and
482 MitoCarta3.0 proteins (lower panel). **C** – Scatter plot showing the correlation between PBMC (SC4) and
483 fibroblast (SC5) samples based on log₂ fold-changes from whole-cell proteins in a diagnosed patient with
484 variants in *MRPL50* relative to controls²¹ showing reduced abundance of the proteins belonging to the large
485 subunits of the mitochondrial ribosome (mtLSU; purple), mtSSU = mitoribosome small subunit (orange).
486 **D** – Volcano plot of whole cell proteins from UDP6 (*NDUFA13*) PBMCs compared to controls (N=5) showing
487 reduced abundance of *NDUFA13* (orange dot) and other structural subunits of Complex I. Vertical lines
488 represent ± 2 -fold-change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent.
489 Blue = Complex I subunits. **E** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP6
490 (*NDUFA13*) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar
491 represents mean complex abundance. Upper and lower bars represent 95% confidence interval.
492 Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, * =
493 p<0.05, ns = not significant, p>0.05. **F** – Protein range for *NDUFA13* in PBMCs in UDP6 (*NDUFA13*, red
494 dot) and controls (N=5, purple dots) showing standard deviation of -12.2 from the control median. **G** –
495 Volcano plot of whole cell proteins from UDP7 (*NDUF6*) PBMCs compared to controls (N=5) showing
496 reduced abundance of *NDUFS8* and other structural subunits of Complex I. Vertical lines represent ± 2 -
497 fold-change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue =
498 Complex I subunits. **H** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP7
499 (*NDUF6*) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar
500 represents mean complex abundance. Upper and lower bars represent 95% confidence interval.
501 Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, **
502 = p<0.01, ns = not significant, p>0.05. **I** – Timeline for ultra-rapid proteomics from PBMC sample receipt to
503 results for UDP8 (*NDUFS8*) case achieved in less than 3 business days. **J** – Volcano plot of whole cell
504 proteins from UDP7 (*NDUFS8*) PBMCs compared to controls (N=5) showing reduced abundance of
505 *NDUFS8* protein (orange dot) and other structural subunits of Complex I. Vertical lines represent ± 2 -fold-
506 change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue = Complex I
507 subunits. **K** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP8 (*NDUFS8*) PBMCs
508 compared to controls (N=5) showing isolated Complex I defect. Middle bar represents mean complex
509 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a
510 paired t-test between the individual protein means. **** = p<0.0001, ** = p<0.01, * = p<0.05, ns = not
511 significant, p>0.05. **L** – Protein range for *NDUFS8* in PBMCs in UDP8 (*NDUFS8*, red dot) and controls (N=5,
512 purple dots) showing standard deviation of -9.3 from the control median.

513

514 **UDP6 (*NDUFA13*)**

515 UDP6 (*NDUFA13*) presented at 2 years of age with chronic ataxia. She was the first child
516 to non-consanguineous healthy parents from Iran and had a healthy 2-month-old brother.
517 There was no family history of any neurological issues. She presented with chronic, stable
518 ataxia, having been unsteady and falling frequently since she started walking at 14
519 months of age. She had mild fine motor delay and a tremor. Her social, language, and
520 cognitive development was age appropriate. On examination, UDP6 (*NDUFA13*) had
521 normal growth parameters and was not dysmorphic. She had mild gait ataxia with a broad
522 base. Her tone, power and reflexes were normal in upper and lower limbs bilaterally.

523 Ophthalmology examination was unremarkable. Magnetic resonance imaging (MRI) of
524 brain showed bilateral symmetrical T2/FLAIR hyperintensity of the cerebral peduncles of
525 the midbrain (and possibly the substantia nigra) and two symmetrical foci of high signal
526 in the dorsal medulla with diffusion-weighted imaging (DWI) restriction. There were no
527 basal ganglia or thalamic abnormalities. This was suggestive of a mitochondrial disorder.
528 Serum blood lactate was elevated 2.4 (RR 1.0-1.8). Other metabolic investigations were
529 normal. Audiology assessments and echocardiogram were normal. At 4 years of age, she
530 has ongoing mild ataxia that improved with physiotherapy and was no longer falling. She
531 has recently had deterioration in her vision and been diagnosed with optic neuropathy.
532 Trio exome sequencing identified compound heterozygous variants
533 NM_015965.7(*NDUFA13*):c.170G>A; p.(Arg57His) likely pathogenic/Class 4 and
534 NM_015965.7(*NDUFA13*):c.187G>A; p.(Glu63Lys) VUS/Class 3. Proteomics was sought
535 to provide functional evidence for the VUS/Class 3 variant and blood was collected for
536 PBMC isolation as fibroblasts were not available at the time of analysis. Five unrelated
537 PBMCs from age-matched normal donors were used as controls. A volcano plot showed
538 reduction of *NDUFA13* protein and several other Complex I subunits in UDP6 (*NDUFA13*)
539 (**Fig. 4D**) and RCA quantified the isolated Complex I defect at 47% control satisfying the
540 criteria for a major defect (**Fig. 4E**). Analysis of the level of the *NDUFA13* protein in the
541 proband demonstrated a residual abundance of 39%, which corresponds to greater than
542 12 standard deviations below the control median (**Fig. 4F**). Proteomics data were
543 subsequently used as functional evidence to upgrade the
544 NM_015965.7(*NDUFA13*):c.187G>A;p.(Glu63Lys) variant to likely pathogenic/Class 4.

545

546 **UDP7 (*NDUFAF6*)**

547 UDP7 (*NDUFAF6*) was referred to the study at five months of age with asymmetric early
548 onset growth restriction, central hypotonia, proximal renal tubular dysfunction, macrocytic
549 anaemia, severe exocrine pancreatic insufficiency, liver dysfunction with cholestasis and
550 mild persistent elevated lactate in CSF and blood. MRI showed symmetrical diffusion
551 abnormality involving corticospinal tract, areas of brainstem and medial cerebellar
552 hemisphere. He died at seven months of age due to progressive bulbar dysfunction with
553 a probable clinical diagnosis of Leigh syndrome. Clinical trio WES identified a single

554 pathogenic (Class 5) heterozygous NM_000262.3(*NAGA*):c.973G>A; p.(Glu325Lys)
555 variant, and two *in trans* variants in *NDUFAF6*, a frameshift
556 NM_152416.4(*NDUFAF6*):c.267delT, p.(Tyr323Ilefs*18) variant and a deep intronic
557 variant, NM_152416.4(*NDUFAF6*):c.298-768T>C, both classified as VUS/Class 3.
558 PBMCs were the sample of choice due to lower invasiveness and potential for fast
559 turnaround. Whole-cell proteomics identified no changes in the abundance of *NAGA*
560 protein relative to controls (**Fig 4G**). *NAGA* encodes the alpha-N-
561 acetylgalactosaminidase, a lysosomal enzyme whose deficiency causes a rare
562 autosomal recessive lysosomal storage disorder. Previous reports of *NAGA*-deficiency
563 show heterogenous presentations ranging from infantile-onset neuroaxonal dystrophy
564 (Schindler disease type I, MIM [609241](#)) to an adult-onset disorder characterised by
565 angiokeratoma corporis diffusum and mild intellectual impairment (Schindler disease type
566 II, also known as Kanzaki disease MIM [609242](#))⁵¹. In addition to the proteomic studies,
567 *UDP7* (*NDUFAF6*) did not appear to have clinical features consistent with *NAGA*-
568 deficiency, and infants with this condition typically develop normally until about a year old.
569 We then turned our investigations to *NDUFAF6* (*C8orf38*) which encodes an assembly
570 factor involved in biogenesis of the core peripheral arm subunit *NDUFS8* of Complex I⁵²
571 and has previously been associated with the stability of the ND1 module of Complex I⁵³.
572 ⁵⁴. Previous reported cases of pathogenic variants in *NDUFAF6* present with a range of
573 symptoms, including Leigh syndrome and the Acadian variant of Fanconi syndrome 5
574 (proximal renal tubular dysfunction) (FRTS5, MIM 618913)⁵³⁻⁵⁷. *UDP7* (*NDUFAF6*) had
575 clinical features consistent with Leigh syndrome, and while the aetiology of his liver
576 dysfunction and severe exocrine pancreatic insufficiency was somewhat less clear, both
577 would broadly fit with a mitochondrial cytopathy noting Complex I deficiencies often do
578 not correlate perfectly with a single clinical subdivision. The
579 NM_152416.4(*NDUFAF6*):c.298-768T>C variant has been reported as likely pathogenic
580 previously, specifically in relation to the FRTS5 phenotype⁵⁶. A volcano plot from whole-
581 cell PBMC proteomics data showed reduction in the abundance of several subunits of
582 Complex I in *UDP7* (*NDUFAF6*), including *NDUFS8*, (**Fig. 4G**) with RCA analysis
583 quantifying the isolated Complex I defect with a major defect of 34% relative to controls
584 (**Fig. 4H**). Functional proteomic data and phenotype match support *NDUFAF6* as being

585 the causative gene for this clinical case, and the VUS/Class 3 variants are in the process
586 of re-curation at the time of writing.

587

588 **UDP8 (*NDUFS8*)**

589 UDP8 (*NDUFS8*) was a neonate admitted to hospital presenting with persistent lactic
590 acidemia, hypertrophic cardiomyopathy, left pulmonary artery stenosis, thickened
591 pulmonary valve, hypotonia and microcephaly with progressive deterioration from 4 weeks
592 of age, succumbing at 5 weeks of age. Brain MRI showed abnormalities in the corpus
593 callosum and diffuse increased signal throughout the supratentorial white matter with
594 small foci of gliosis in the peritrigonal regions. Ultra-rapid trio WGS identified a
595 homozygous intronic variant NM_002496.4(*NDUFS8*):c.501+5G>A with biparental
596 inheritance. Due to the critical deteriorating condition, blood was collected from the
597 proband and subjected to ultra-rapid proteomics. Five unrelated age-matched controls
598 were used for comparison and the complete analysis was performed with a 54-hour
599 turnaround time (TAT) from PBMC sample reception to the reporting of results to the
600 clinical team (**Fig. 4I**). Whole-cell proteomic analysis of PBMCs showed significant
601 reduction of several Complex I subunits, including *NDUFS8* (**Fig. 4J**) and RCA analysis
602 showed an isolated Complex I defect with a major defect of 22% relative to controls (**Fig.**
603 **4K**). Residual abundance of the *NDUFS8* protein in the proband was quantified at 20%,
604 representing over 9 standard deviations below the control median (**Fig. 4L**). The strong
605 phenotype match together with functional evidence from proteomics support disease
606 causation due to variants in *NDUFS8* and leading to variant upgrade to likely
607 pathogenic/Class 4.

608

609 **Discussion**

610 The estimated prevalence of rare disease in the population is in the range of 3.5-6%,
611 equivalent to 263-446 million individuals worldwide⁵⁸. There are over 7,000 different rare
612 diseases known, with a current diagnostic yield of ~35-70% from WES or WGS¹⁻⁵.
613 Mitochondrial disease is a group of rare diseases caused by variants in over 300 known
614 genes^{6, 16}, where RCE has been historically performed to confirm a specific OXPHOS
615 defect in the functional validation of variant pathogenicity¹⁶.

616

617 We have previously used an approach we term relative complex abundance (RCA) where
618 proteomics data are used to quantify the residual abundance of OXPHOS complexes in
619 clinical samples from individuals suspected of mitochondrial disease. We have shown
620 that RCA acts as an effective proxy for clinically accredited RCE, including when
621 appropriate samples have not been available^{20-22, 24, 25, 59-61}. In an RCA analysis, the
622 abundance of a complex in a sample is calculated from the mean of each individual
623 subunit abundance detected by more than two peptides across each complex. The power
624 of RCA analysis relies on the quantification of multiple peptides per protein in a complex
625 with a high degree of subunit stability co-dependence, as we and others have previously
626 shown for Complex I, III, IV, the mitoribosome^{11, 17, 20-22, 25, 59, 60, 62, 63} and non-mitochondrial
627 complexes such as the exocyst and nuclear pore complexes^{64, 65}. RCE, on the other hand,
628 typically relies on enzyme rate estimates determined in several replicates of patient
629 samples and compared against age-matched controls. In some instances, we have found
630 RCA demonstrated higher sensitivity by detecting a specific OXPHOS defect where RCE
631 was inconclusive^{20, 22}. RCA can also show higher specificity for use in functional validation
632 of variant pathogenicity by detecting reduction of specific parts of the complex (e.g. loss
633 of subunits in the catalytic Complex I N-module in VC1-*NDUFAF2* and VC2-*NDUFS6*),
634 implicating only the 10 N-module subunits as candidate genes compared with loss of
635 Complex I RCE potentially being caused by variants in any of more than 50 genes
636 encoding Complex I subunits and assembly factors^{26, 66}. In other cases, some variants
637 encoded by the mtDNA resulted in no defect on RCA analysis despite over 70% and 90%
638 heteroplasmy levels in fibroblasts. This suggests that some mtDNA variants can be
639 refractive to RCA analysis due to an enzymatic and not a structural defect, where RCE
640 might be an appropriate test to provide functional evidence. In terms of variant type,
641 mitochondrial DNA variants account for only 0.54% of rare diseases while autosomal
642 recessive variants account for over 41%⁶⁷ and are more likely to result in a loss-of-
643 function protein⁶⁸, which can be detected via quantitative proteomics.

644

645 RCE is typically performed on a tissue biopsy sample (e.g. skeletal muscle, liver) or
646 primary cultured cells (e.g. fibroblasts). Establishing and growing primary fibroblasts from

647 skin biopsies to a sufficient volume of cells for RCE analysis involves weeks to months of
648 cell culture⁴⁹, and, in some cases, tissue specificity results in only mild or undetectable
649 defects as measured by RCE¹⁰. Here we have demonstrated the feasibility of using
650 PBMCs in diagnostic proteomics testing. In our hands, sufficient PBMCs for these
651 analyses can be readily obtained from as a little as 1 ml of whole blood and the process
652 from PBMC isolation to data acquisition performed in less than 48 hours. Together these
653 properties and the results presented in this study demonstrate that PBMCs can be
654 combined with our ultra-rapid proteomics pipeline for functional validation of variants
655 causing defects in the mitochondrial OXPHOS system and the mitoribosome.

656
657 The untargeted nature of quantitative proteomics also allows this technique to be applied
658 beyond mitochondrial disease, as we have shown here for a mitochondrial disease
659 phenocopy (UDP4; *CCDC47*) and elsewhere for nuclear pore, neuronal exocytic vesicle
660 trafficking and rigid spine disorders^{64, 65, 69}. Over 50% of known disease-associated
661 genes²⁷ are routinely detected by our quantitative proteomics pipeline in PBMCs or
662 fibroblasts, and over 45% of all disease genes listed in OMIM are part of a protein
663 complex¹⁶. This means that pathogenic variants in one of these genes can lead to
664 reduction of the protein of interest, which in some cases will result in downstream complex
665 reduction as an additional layer of functional evidence to support variant upgrade. In
666 terms of variant type, we show that quantitative proteomics can provide functional
667 evidence for a wide range of genetic variants including CNV⁶², splice site and deep
668 intronic^{20, 22}, and missense variants²¹. Missense variants are the most common type of
669 variant accounting for 60% of pathogenic variants associated with autosomal recessive
670 disorders¹⁸ and are usually refractory to transcriptomic analysis. For some cases,
671 proteomics can also provide supportive functional evidence supportive when the protein
672 encoded by the candidate gene is not detectable, either due to protein abundance being
673 below the limit of detection or for genes encoding tRNAs, as seen in VC22 (*MT-TK*),
674 further expanding the potential application of proteomics in rare disease diagnosis.

675
676 A genomics-first approach to rare disease diagnosis has markedly increased diagnostic
677 rates and, in the case of rapid and ultra-rapid genomic testing, shortened diagnostic

678 odysseys to days instead of months^{65, 70-72}. In the case of mitochondrial and many other
679 rare diseases, diagnoses are often now achieved using just a blood sample, sparing many
680 patients from an invasive biopsy of muscle or other tissues. As a result, diagnostic centres
681 such as ours now receive a third or less of the number of samples for RCE testing than
682 received 10 years ago. This provides an incentive for untargeted functional tests, such as
683 RNA sequencing and proteomics, that could be financially viable and widely available in
684 a pathology-certified context.

685
686 This study also highlights the limitations of quantitative proteomics in detecting
687 abundance changes in variants leading to catalytic defects and some mtDNA-encoded
688 variants in fibroblasts. Moreover, the detection of proteins is related to the limit of
689 detection as determined by the liquid chromatography, mass-spectrometry
690 instrumentation, and data acquisition methods used. However, recent advances in mass-
691 spectrometry instrumentation including development of the asymmetric track lossless
692 (Astral) analyzer offer further improvements in sensitivity and greatly reduced run times⁷³.
693 Quantitative proteomics thus offers a further paradigm shift by providing functional
694 evidence for variants in thousands of genes in a single test. This driver will facilitate the
695 translation of proteomics testing for rare diseases into certified pathology laboratories.
696 Clinically delivered proteomics can potentially replace hundreds of tests targeted to
697 specific diseases, which are usually restricted to research settings and carry less weight
698 in the upgrade of variants. Our study also demonstrates that proteomics can be delivered
699 alongside ultra-rapid genomic sequencing approaches to provide functional data in a
700 clinically relevant timeline.

701

702 **Materials and Methods**

703 *Ethics statement*

704 This study was conducted in accordance with the revised Declaration of Helsinki and
705 following the Australian National Health and Medical Research Council statement of
706 ethical conduct in research involving humans. Samples were obtained after receiving
707 written, informed consent for diagnostic or research investigations from the respective
708 responsible human ethics institutional review boards. HREC/RCH/34228,
709 HREC/RCH/34183, HREC/89419/RCHM-2022 and HREC/82160/RCHM-2022 were

710 approved by the Royal Children's Hospital, Melbourne, Ethics in Human Research
711 Committee. HREC/16/MH/251 was approved by the Melbourne Health Human Research
712 Ethics Committee. The REC reference 2002/205 by the Newcastle and North Tyneside
713 Local Research Ethics Committee.

714

715 *Genomic investigations*

716 Genomic investigations resulting in diagnosis of patients within the validation cohort (VC)
717 are described in the publications indicated by PMID within **Supplementary Table 1**, with
718 the exceptions of VC13 (*SDHAF1*), VC15 (*UQCRC2*) and VC24 (*FARS2*) which are as
719 follows; Individual VC13 (*SDHAF1*) underwent clinical singleton WES through Baylor
720 Genetics as previously described⁷⁴. For individual VC15 (*UQCRC2*), homozygosity
721 mapping from Illumina HumanCytoSNP-12 v2.1 array data identified substantial long
722 contiguous stretches of homozygosity (LCSH) accounting for ~3.7% of the genome. Due
723 to the observed complex III RCE defect in this patient, candidate gene sequencing of
724 exons using genomic DNA through PCR and sanger sequencing was performed on
725 complex III-related genes *UQCC1* and *UQCRC2* which lay within these regions of LCSH
726 (primers available upon request). Blood DNA for individual VC24 (*FARS2*) underwent
727 clinical singleton WES testing through the Victorian Clinical Genetics Service (VCGS) as
728 previously described⁷⁵. mtDNAseq was also used to quantify mtDNA variant
729 heteroplasmy levels for individuals VC6 (*MT-ND1*) and VC12 (*MT-ND5*) as previously
730 described⁷⁵. Individuals within the undiagnosed patient (UDP) cohort were investigated
731 as follow: blood DNA from UDP1 (*MT-ATP6*) underwent WES with mitochondrial DNA
732 sequencing (mtDNAseq) as part of the Australian Genomics Mitochondrial Flagship as
733 described⁷⁵. For individual UDP4 (*CCDC47*), sequencing and analysis was performed as
734 previously described²⁵. Individual UDP5 (*NDUFA10*) had the Comprehensive Metabolism
735 Panel performed by Blueprint Genetics. Individuals UDP6 (*NDUFA13*) and UDP7
736 (*NDUFAF6*) both underwent clinical trio WES through the Victorian Clinical Genetics
737 Service (VCGS)⁷⁵. UDP8 (*NDUFS8*) had acute-care rapid trio WGS and analysis at the
738 VCGS as previously published⁶⁵.

739

740 *Respiratory chain enzymology*

741 Respiratory chain enzyme activities in fibroblasts and skeletal muscle were measured by
742 spectrophotometry as described¹⁰. Complex I (CI) was measured as rotenone-sensitive
743 NADH:coenzyme Q₁ oxidoreductase, Complex II (CII) as succinate:coenzyme Q₁
744 oxidoreductase, Complex III (CIII) as decylbenzylquinol:cytochrome c reductase, and
745 Complex IV (CIV) as cytochrome c oxidase. Citrate synthase (CS) was measured as

746 production of coenzyme A (CoA.SH) from oxaloacetate using the thiol reagent 5,5'-dithio-
747 bis-(2-nitobenzoic acid). Enzyme activities were calculated as initial rates (CI, CII, and
748 CS) or as first-order rate constants (CIII and CIV)¹⁰.

749

750 *Cell Culture Conditions*

751 Fibroblast and HEK293T cell lines were cultured in Dulbecco's Modified Eagle Medium
752 (DMEM) High Glucose, Sodium Pyruvate and Glutamine (Sigma-Aldrich) supplemented
753 with 10% (v/v) Fetal Calf Serum (FCS; CellSera), 100 U/mL Penicillin-Streptomycin
754 (Gibco) and 50 µg/mL Uridine. Cells were maintained at 37°C with 5% CO₂.

755

756 *Generation of knockout lines*

757 The NDUFS2^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding the
758 guide RNA 5'-TGAGGGCTTTGTGCGGCTTCCGG-3' cloned into the pSpCas9-2A-GFP
759 vector²⁶. The CRISPR was transfected into HEK293T cells and single cells were obtained
760 by Fluorescence-activated cell sorting at the Monash Flow Cytometry Platform (Flowcore).
761 Single cell populations were screened by loss of cell viability on galactose-containing
762 DMEM and subsequently validated by the loss of protein by western blotting and indel
763 sequencing, which identified two deletions c.[18_36del] and c.[17_42del] (Supplementary
764 table 1). The UQCRC2^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding
765 the guide RNA 5'-CACCGGTACTTACACATCACCCCGC designed using the
766 CHOPCHOP tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously
767 described²⁶. The plasmids were validated by sequencing, and then transfected into target
768 cell lines using Lipofectamine™ 3000 Transfection Reagent (Thermo Fischer Scientific)
769 according to manufacturer's guidelines. Single cells expressing GFP were isolated on a
770 FACS Aria Fusion (BD Biosciences) cell sorter and clonal populations were subsequently
771 screened for relevant gene knockouts using SDS-PAGE and immunoblotting and indel
772 sequencing, which identified two deletions c.[9141_9199del] and [9146_9167del]
773 (Supplementary table 1). The SURF1^{KO} cell line was generated using a CRISPR/Cas9
774 system with the HEK293T parental cell line. Two guide RNAs targeting the 5'UTR and
775 exon 2 regions of *SURF1* were cloned into individual pSpCas9-2A-GFP vectors (Addgene,
776 plasmid 48138¹⁸). Both constructs were transfected simultaneously into HEK293T cells
777 using Lipofectamine 3000 (Thermo Fisher Scientific), according to the manufacturer's
778 instructions. Verification of successful HEK293T SURF1^{KO} was performed via three
779 primer screening PCR were used to amplify incorporated indels via PCR and by SDS-
780 PAGE immunoblotting. The product of external Primers (outside the double CRISPR
781 target sites) underwent M13 primer Sanger Sequencing of alleles, using the Topo™ TA

782 Cloning Kit (Thermo Fisher Scientific) as per the manufacturer's instructions. Sequencing
783 identified two deletions [c.18_219del] and [c.18_221delinCG] (Supplementary table 1).
784 The ATP5PD^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding the
785 guide RNA 5'-CACCGCCTTTCCTTGTGGGCAGGT designed using the CHOPCHOP
786 tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously described²⁶. The
787 plasmids were validated by sequencing, and then transfected into target cell lines using
788 Lipofectamine™ 3000 Transfection Reagent (Thermo Fischer Scientific) according to
789 manufacturer's guidelines. Single cells expressing GFP were isolated on a FACS Aria
790 Fusion (BD Biosciences) cell sorter and clonal populations were subsequently screened
791 for relevant gene knockouts using indel sequencing, which identified a single deletion
792 c.[33481insT] (Supplementary table 1).

793

794 *PBMC isolation from whole blood*

795 Neonatal blood samples were collected from healthy neonates following routine
796 intramuscular administration of Vitamin K. For older infants and children ages 30 days to
797 18 years, venous blood samples were obtained from hospital outpatients undergoing
798 minor elective day surgery. An outline of the study protocol and complete detail of
799 participant recruitment, inclusion and exclusion criteria and sample collection are
800 described in our previously published HAPPI Kids study protocol⁷⁶. PBMCs were isolated
801 from fresh blood samples of the 37 HAPPI Kids controls using Ficoll®-Paque Plus (GE
802 Healthcare Life Sciences) according to the instructions of the manufacturer with manual
803 removal of the PBMC layer using a Pasteur pipette. For the UDP6 (*NDUFA13*), UDP7
804 (*NDUFAF6*) and UDP8 (*NDUFS8*) probands, PBMC isolation using Ficoll®-Paque Plus
805 was performed in SepMate™ tubes (STEMCELL Technologies), based on
806 manufacturer's protocols with moderate braking applied for both washes, and a reduction
807 in centrifugation speed and duration to 200 g for five minutes for the second wash.

808

809 *Data-Independent Acquisition Mass Spectrometry of Fibroblast, HEK293T and PBMCs* 810 *Cohorts and Data Analysis*

811

812 *Spectral Library Sample Preparation*

813 A HEK293T spectral library was generated from both whole cell and mitochondrial
814 HEK293T samples to search data-independent acquisition (DIA) HEK293T knockout cell
815 lines. A total of 100 µg of mitochondrial sample isolated from wildtype HEK293T cells
816 underwent carbonate extraction at pH 11.5 to separate soluble and integral mitochondrial
817 proteins, as previously described⁷⁷. The resulting pellet and supernatant samples, as well

818 as 25 µg whole cell HEK293T sample, were solubilized in lysis buffer for a final
819 composition of 5% SDS and 50 mM Triethylammonium bicarbonate (TEAB) pH 8.5. The
820 lysed whole cell, mitochondrial pellet and supernatant samples were processed using S-
821 trap™ Micro Spin Columns (ProtiFi) according to the manufacturer's instructions, where
822 samples were reduced with 40 mM 2-chloroacetamide (CAA, Sigma) and alkylated with
823 10 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; BondBreaker, Thermo
824 Fischer Scientific). Isolated proteins were digested at 1:25 trypsin to protein ratio at 37°C
825 overnight and eluted peptides were dried down using a CentriVap Benchtop Vacuum
826 Concentrator (Labconco). Fibroblasts and PBMCs spectral libraries were generating from
827 whole cell samples of either five healthy fibroblast controls or PBMC pellets isolated from
828 39 healthy individuals ranging from 0-17 years old. Fibroblast or PBMC pellets were
829 solubilized 5% SDS and 50 mM TEAB pH 8.5, and total protein determined by Pierce
830 bicinchoninic acid (BCA) Protein Assay Kit (Thermo Fisher Scientific). A total of 25 µg for
831 each control was processed using the S-Trap™ Micro Spin Columns (ProtiFi), as
832 described above.

833 Peptides from HEK293T, fibroblast and PBMC samples were reconstituted in 0.5% formic
834 acid (FA) for fractionation. Fibroblast and PBMC control samples were pooled upon
835 reconstitution to create a single fibroblast, HEK293T and PBMC peptide mixture and
836 loaded onto a strong cation exchange (Empore Cation Exchange-SR, Supelco Analytical)
837 stage-tips made as described⁷⁸. Stage tips were washed with 20% acetonitrile (ACN) and
838 0.5% FA and eluted over seven fractions of increasing concentrations of ammonium
839 acetate (45-300 mM), 20% ACN and 0.5% FA for whole cell fibroblasts, PBMC and
840 HEK293T samples. HEK293T mitochondrial and supernatant samples, were collected
841 over five fractions. All samples underwent a final elution with 5% ammonium hydroxide
842 and 80% ACN, followed by concentration using a CentriVap Benchtop Vacuum
843 Concentrator (Labconoco). Fractions were desalted on SDB-XC (poly(styrene-divinyl-
844 benzene); Supelco Analytical) stage tips made in-house as previously described⁷⁸.

845

846 *Spectral Library Mass Spectrometry Data Dependent Acquisition*

847 Fractions were reconstituted in 0.1% trifluoroacetic acid (TFA) and 2% ACN and each
848 library was analyzed by liquid chromatography (LC)-tandem mass spectrometry (MS/MS)
849 on an Orbitrap Eclipse Mass Spectrometer (Thermo Fischer Scientific) operating on DDA
850 mode over a 125-minute gradient. Tryptic peptides were loaded onto an Acclaim Pepmap
851 nano-trap column (Dinoex-C18, 100 Å, 75 µm × 2 cm) at an isocratic flow of 5 µl/min of
852 2% ACN and 0.1% FA for six minutes before switching with an Acclaim Pepmap RSLC
853 analytical column (Dinoex-C18, 100 Å, 75 µm × 50 cm). The separation of peptides was

854 performing using a nonlinear 125-minute gradient of solvent A (5% dimethyl sulphoxide
855 (DMSO), 0.1% FA) and solvent B (5% DMSO, 100% ACN, 0.1% FA). The flow gradient
856 was (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-
857 40% solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent
858 B, (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes
859 before the next injection. Briefly, the data was collected using positive polarity with a MS1
860 scan range of 375-1500 m/z and resolution set to 120,000. Other MS1 instrument
861 parameters include: ACG target of 4e5, maximum injection time of 50 ms and Isolation
862 window of 1.6. MS2 instrument parameters include: scan range of 150-2000 m/z,
863 resolution of 15,000, HCD collision energy of 30%, ACG target of 5e3, maximum injection
864 time of 22 ns and dynamic exclusion of 30 s. Raw files were imported into Spectronaut^{®79}
865 (v.15.2.210819.50606 for HEK293T library, v.14.8.201029.4778 for fibroblasts library, v.
866 16.0.220606.53000 for PBMCs library) and the three libraries were generated using the
867 'Pulsar' option with default BGS Factory settings, searching against Uniprot human
868 database containing reviewed canonical and isoforms sequences (42,386 entries). The
869 resulting HEK293T library contained 194,270 precursors, the fibroblast library contained
870 131,627 precursors, and the PBMC library contained 148,522 precursors.

871
872 *Sample Preparation of HEK293T, PBMC and Fibroblast Cell Lines*
873 Whole cell pellets of HEK293T cells, PBMCs and fibroblasts were collected and washed
874 twice with PBS before resuspension in 5% SDS, 50 mM tetraethylammonium bromide
875 (TEAB) pH 8.5 buffer and 125 U of benzonase per ml (Sigma-Aldrich). Skeletal muscle
876 samples were solubilized with a probe sonicator with 30% amplitude in 5% SDS, 50 mM
877 TEAB pH 8.5 buffer on ice with a cycle of 10 seconds on 10 seconds off for 1 minute and
878 clarified at 16,000 x g for 5 minutes. Protein concentration was performed with Pierce
879 BCA Protein Assay Kit (Thermo Fisher Scientific) and 25 µg of each sample was aliquoted
880 in triplicates for patients and singlicate for individual controls (N=3-5). Samples were
881 processed using S-trap[™] micro spin columns (ProtiFi) according to the manufacturer's
882 instructions. Proteins were digested with trypsin (Thermo Fisher Scientific) at 1:10 trypsin
883 to protein ratio. Peptides were dried down using a CentriVap Benchtop Vacuum
884 Concentrator (Labconco) and reconstituted in 45 µL 2% ACN, 0.1% trifluoroacetic acid
885 (TFA) and 2 µL injected for liquid chromatography tandem mass spectrometry (LC-
886 MS/MS). Samples were analyzed for 125 minutes (HEK293T) or 95 minutes (Fibroblasts,
887 skeletal muscle, PBMCs) on an Orbitrap Eclipse mass spectrometer (Thermo Fisher
888 Scientific) operating in DIA mode.

889

890 *Mass Spectrometry Data Independent Acquisition*

891 Peptides were reconstituted in 45 μ L of 2% ACN and 0.1% TFA and 2 μ L was injected into
892 an Orbitrap Eclipse mass spectrometer (Thermo Fischer Scientific) for LC-MS/MS
893 analysis equipped with trap and analytical columns described above. All samples were
894 analysed with the mass spectrometer operating in DIA mode. The separation of peptides
895 was performed using a nonlinear gradient of solvent A and solvent B across 125-minutes
896 for HEK293T knockout cell lines, and 95-minutes for all other sample types (fibroblasts,
897 PBMCs and skeletal muscle). Briefly, for the 125-minute method, the flow gradient was
898 (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-40%
899 solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent B,
900 (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes
901 before the next injection. The data was collected using positive polarity with a MS1 scan
902 range of 350-1200 m/z at a resolution of 120,000. Other MS1 instrument parameters
903 include: ACG target of 1e6, maximum injection time of 50 ms, Isolation window of 24 with
904 1 m/z overlap. For MS2 parameters, the scan range was 200-2000 m/z at 15,000
905 resolution, HCD collision energy of 30%, AGC target of 1e6 and maximum injection time
906 of 22 ms. For the 95-minute method, the flow gradient was (i) 0-6 min at 3% solvent B,
907 (ii) 6-7 min at 3-4% solvent B, (iii) 7-82 min at 4-25% solvent B, (iv) 82-86 min at 25-40%
908 solvent B, (v) 86-87 min at 40-80% solvent B, (vi) 87-90 min at 80-80% solvent B, (vii) 90-
909 91 min at 80-3% solvent B and equilibrated at 3% solvent B for 5 minutes before the next
910 injection. Instrument parameters were consistent with those used in the 125-minute
911 method described above, with changes made to the following parameters: MS1 scan
912 range of 350-1400 m/z, MS1 maximum injection time of 45 ms, Isolation window of 13.7
913 and MS2 ACG target of 5e5.

914

915 *Proteomic data search*

916 Raw data analysis was conducted with Spectronaut^{®79} (v.15.2.210819.50606) against the
917 spectral libraries generated above. Default BGS Factory search parameters were used
918 with changes made to exclude single hit proteins, no selection of 'Major Group Top N'
919 and 'Minor Group Top N' and data filtering setting set to 'Q-value' or 'Q-value sparse' with
920 'run-wise imputation' as an imputing strategy. 'Q-value' datasets (unimputed) were used
921 for generation of RCA values while 'Q-value sparse' with 'run-wise imputation' datasets
922 were used to generate volcano plots, heatmaps and correlation plots to reduce missing
923 values for visualization.

924

925 *Protein filtering and clean up*

926 Proteins were filtered in each cohort to ensure that the data was of high quality and with
927 a minimal amount of missing data for analysis. Proteins within the validation cohort (VC)
928 were filtered out if identified by a single peptide in all controls or proband samples,
929 maintaining proteins that were identified by >2 peptides in both groups. Proteins were
930 then filtered to least three or more valid values for the controls and at least two or more
931 valid values for the proband samples. For the knockout cohort (KC), proteins were filtered
932 out if identified by a single peptide in all controls and proband samples. Proteins were
933 then filtered to at least two valid values for the controls and at least two valid values for
934 the knockout sample. For the undiagnosed proband cohort (UDP), proteins were filtered
935 out if identified by a single peptide in all controls or proband samples. Proteins were then
936 filtered for 70% valid values for the controls due to the different number of controls per
937 batch and 70% valid values for the proband samples. For the supporting cohort (SC),
938 samples SC1, SC2, SC3 and SC5 proteins were filtered out if identified by a single peptide
939 in all controls or proband samples. Proteins were then filtered for 70% valid values for the
940 controls and 70% valid values for the proband samples. Sample SC4 had no filtering
941 completed as this was a previously published dataset²¹ and the data was unlogged and
942 complex subunit gene names manually updated to match the current MitoCarta3.0
943 naming convention for Complex V subunits. For the 36 PBMC control samples (SC6-41),
944 proteins were filtered out if they were identified by a single peptide across all 36 samples
945 and further filtered for at least 70% valid values.

946

947 *Relative Complex Abundance Plots.*

948 Relative complex abundance (RCA) plots were generated for all VC, KC, SC and UDP
949 cohorts and plots can be viewed within the RDMS Explorer platform. All samples
950 underwent mitochondrial normalization where the mean of the mitochondrial proteins for
951 each specific sample was determined using the average of all control mitochondrial
952 proteins or proband mitochondrial proteins and then used as a normalization factor for
953 each group and applied to each sample. To develop the RCA plots, the average of the
954 proband and controls was determined and then transformed to log₁₀. The difference
955 between the log₁₀ of the proband and controls was determined and then unlogged.
956 Statistical difference between the control and proband complex subunits was determined
957 using a paired t-test and summary statistics including mean and the error bars indicating
958 standard deviation were determined for each complex and the graph plotted within R
959 (v.4.3.2). Complex subunits were determined using curated annotations from
960 MitoCarta3.0²⁸. Mitochondrial abundance plots were generated using log₂ abundances
961 of MitoCarta '+' entries for each batch and significance performed with an ANOVA test.

962

963 *Protein range graphs*

964 Protein range graphs were developed using an in-house R script. The median of the
965 protein of interest in control samples is calculated as well as the median of the proband
966 replicates. The log₂ fold-change is calculated between the proband and control and
967 converted to percentage for the proband as the abundance relative to the control median
968 for plotting. The range of the controls is also displayed as the abundance relative to the
969 control median. The log₂ abundance per standard deviation (SD) is rounded to one
970 decimal place with the top axis SD present to determine how many standard deviations
971 the protein is from the control median.

972

973 *Volcano and Correlation plots*

974 The peptide and valid value cleaned matrices for all samples were annotated with
975 MitoCarta3.0²⁸ entries in Perseus⁸⁰. All analyses were performed in Perseus v 1.6.14.0.
976 Volcano plots were visualized using scatter plot function from a two-sample t-test using
977 p-value threshold of 0.05 in Perseus. For the correlation plots (Fig 3B, Supplementary
978 Fig.2B), proteomic data searched with q-value sparse with run-wise imputation settings
979 were correlated via gene name using gene name entries and the logFCs in R and plotted
980 using scatter plot function in Perseus. For Fig. 4C, previously published data from
981 MRPL50 Fibroblasts²¹ were correlated with MRPL50 PBMCs using gene name entries
982 and the logFCs in R and plotted using scatter plot function in Perseus.

983

984 *RDMS Explorer Website.*

985 All the code used to develop the RDMS Explorer website
986 (<https://rdmassspec.shinyapps.io/RDMSExplorer/>) and in-house analysis performed in R
987 can be found at DOI: 10.5281/zenodo.12883603.

988

989 *Heatmaps, Venn diagrams and Donut plots*

990 For heatmaps output matrices searched with q-value sparse run-wise imputation settings
991 Spectronaut runs were log₂ transformed and a two-sided t-test using p-value for
992 truncation was performed in Perseus for each cell line against their respective batch
993 controls. The Morpheus software was used for heatmap visualization
994 (<https://software.broadinstitute.org/morpheus>). For Supplementary Fig. 1A, proteins were
995 manually annotated based on MitoCarta3.0 as 'assembly factor' or 'complex I-V' and
996 subset for visualization in Morpheus using the following parameters metric 'one minus
997 Pearson correlation', linkage method 'average', cluster 'rows' and group columns by

998 'complex/assembly factor'. P-value results from t-test statistical analysis were used to
999 visualize the significance of each data point by overlaying the p-value matrix onto the t-
1000 test matrix in Morpheus and using the option size by 'p-value matrix' size minimum '0'
1001 and maximum '1.301' (p-value<0.05). For the correlation heatmap plot (Supplementary
1002 Fig. 2A), hierarchical clustering was used with the following parameters in Morpheus:
1003 metric 'one minus Pearson correlation', linkage method 'average' and cluster 'columns'.
1004 Topographical heatmaps (Supplementary Fig. 1B) were generated from log₂-transformed
1005 fold-change from t-test in Pymol using the PDB structures (CI: 5LDW, CII: 1ZOY, CIII:
1006 1BGY, CIV: 5Z62, CV: 7AJD) as previously described²⁶. Venn diagrams were generated
1007 with DeepVenn⁸¹ using gene names. Green (diagnostic-grade) and amber (borderline
1008 diagnostic-grade) lists for mitochondrial disease (v.0.787) and Mendeliome gene lists
1009 (v.0.12869) were retrieved from PanelApp Australia²⁷. Donut plots were generated in
1010 GraphPad Prism (v.10.2.0).

1011

1012 *RNA sequencing and transcriptomic analysis*

1013 RNA sequencing and analysis was performed as described²⁰. In brief, RNA was extracted
1014 from muscle using miRNeasy Mini Kit (Qiagen) and treated with RNase-Free DNase
1015 (Qiagen) and RNA quality and quantity measured using TapeStation RNA ScreenTape
1016 analysis (Agilent) and Qubit RNA HS (Thermo Fisher Scientific). UDP4 underwent
1017 RNAseq within a group of 10 undiagnosed patients with available muscle samples, all
1018 with a RNA integrity number of 7.2 - 8.9. The Kapa Biosystems mRNA Hyper Prep Kit
1019 was used to generate sequencing libraries from 500ng RNA, and paired-end sequencing
1020 on an Illumina instrument was performed at the Yale Center of Genome Analysis to
1021 achieve 50-100 million read coverage.

1022

1023 For outlier detection, 100 control muscle samples were retrieved from GTEx using the
1024 Sequence Read Archive (SRA) toolkit and converted into FASTQ using Fastq-dump.
1025 Patient and control FASTQ files were aligned to hg38 human reference genome with
1026 GENCODE v26 annotations using STAR (v2.5.3a), with twopassMode = 'Basic' to enable
1027 detection of novel splice junctions, and duplicates marked using Picard (v2.9). RNA-
1028 SeQC (v2.3.4) was used to generate quality metrics from STAR-aligned bam files.
1029 Outliers were removed per the following criteria: (a) <45 million QC-passed reads, (b)
1030 <18,000 genes detected and (c) manual identification via Principal Component Analysis.
1031 This resulted in the removal of 11 samples, leaving 89 control samples from muscle.
1032 Outlier expression was assessed using the DROP (Detection of RNA Outliers Pipeline)
1033 pipeline v0.9.0 (<https://github.com/gagneurlab/drop>), with default settings⁸². Analysis was

1034 restricted to 6106 genes, which included Mendeliome and ‘MitoExome’ genes, as
1035 described previously²⁰.

1036

1037 *cDNA studies*

1038 The total RNA extracted from skeletal muscle for RNA sequencing was also synthesized
1039 into cDNA using the SuperScript III First-Strand Synthesis System (Thermo Fisher
1040 Scientific) as per both manufacturer’s protocols and as described previously⁸³. To
1041 examine mRNA splicing in *CCDC47*, PCR primers (5’ GCGTGACTGAGCTACGGTT 3’;
1042 5’ CTCTGGGATGGCTTTACATGG 3’) were designed to amplify the entire ORF from
1043 cDNA. PCR products were analyzed on 1% agarose (Bioline) gels using a 1-kb Plus DNA
1044 Ladder (Thermo Fisher Scientific) prior to cloning into a pCR2.1-TOPO vector using the
1045 TOPO TA cloning kit (Thermo Fisher Scientific) and transformation into TOP10 competent
1046 cells (Thermo Fisher Scientific). Individual colonies were examined and then underwent
1047 sanger sequencing.

1048

1049 **Conflict of Interest**

1050 The authors declare that the research was conducted in the absence of any commercial
1051 or financial relationships that could be construed as a potential conflict of interest.

1052

1053 **MitoMDT Diagnostic Network for Genomics and Omics**

1054 David R Thorburn, Carolyn M Sue, Aleksandra Filipovska, Michael T Ryan, David A
1055 Stroud, Diana Stojanovski, David Coman, Sean Murray, Ryan L Davis, John
1056 Christodoulou, Phillipa J Lamont, Suzanne CEH Sallevelt, Roula Ghaoui, Cas Simons,
1057 Stefan J Siira, Shanti Balasubramaniam, Alison G Compton, Daniel G MacArthur, Nicole
1058 J Lake, Amanda Samarasinghe, Yoni Elbaum, Catherine Atthow, Pauline McGrath,
1059 Ellenore M Martin, Madeleine Harris, Tegan Stait, Leah E Frajman, Simone Tregoning

1060

1061 **Author contribution**

1062 Conceptualization: DHH, DRT, DAS

1063 Methodology: DHH, NJC, LNS, NJL, LuEF, SSCA, TS, ST, LeEF, DRLR, MB, BoR, AGC,
1064 VK, CA

1065 Investigation: DHH, MB, BrR, MJW, AV, CB, HP, JL, ZS, RM, RWT, AGC, WB

1066 Visualization: DHH, NJC, LNS, NJL, SSCA

1067 Website design and coding: NJC

1068 Funding acquisition: DHH, JC, AGC, DRT, DAS

1069 Project administration: AS, RB, DRT, DAS

1070 Supervision: PM, ML, RM, RWT, MTR, ZS, JC, AGC, DRT, DAS

1071 Writing – original draft: DHH, DRT, DAS

1072 Writing – review & editing: all authors reviewed and edited the manuscript

1073

1074 **Funding**

1075 This research was supported by Australian National Health and Medical Research
1076 Council (NHMRC) Project and Ideas grants (1140906 to DAS; 1164479 to DRT; 2010939
1077 to MTR), Investigator Fellowships (2009732 to DAS, 2010149 to LuEF and 1155244 to
1078 DRT) and a Principal Research Fellowship (1155244 to DRT) along with funding by
1079 Australian Genomics Health Alliance (Australian Genomics) NHMRC Targeted Call for
1080 Research grant GNT1113531. Additional support came from the Australian Medical
1081 Research Future Fund Genomics Health Futures Mission (2007959 to DRT) and Acute
1082 Care Genomics (GHFM76747). The US Department of Defense Congressionally Directed
1083 Medical Research Programs (PR170396 to DRT). We thank the Mito Foundation for the
1084 provision of instrumentation through research equipment grants to DAS and DHH.
1085 Additionally, LuEF acknowledges support from the Mito Foundation. This work was also
1086 supported by grants from Royal Children’s Hospital Foundation [2021-1377]. Work at the
1087 MCRI is supported through the Victorian Government’s Operational Infrastructure
1088 Support Program. RWT is funded by the Wellcome Centre for Mitochondrial Research
1089 (203105/Z/16/Z), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Medical
1090 Research Council (MR/W019027/1), the Lily Foundation, Mito Foundation, the
1091 Pathological Society, the UK NIHR Biomedical Research Centre for Ageing and Age-
1092 related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust,
1093 LifeArc and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of
1094 Adults and Children.

1095

1096 **Acknowledgments**

1097 We acknowledge and thank all the families who contributed to this study. We thank all
1098 members of the Stroud and Stojanovski lab for input into experimental design and
1099 interpretation of data. We thank the Bio21 Mass Spectrometry and Proteomics Facility
1100 (MMSPF) for the provision of instrumentation, training, and technical support. The Chair
1101 in Genomic Medicine awarded to JC is generously supported by The Royal Children’s
1102 Hospital Foundation. The authors thank staff of the Pathology Collection Department at
1103 The Royal Children’s Hospital for obtaining the consent of participants and the collection
1104 of samples. The authors thank staff of the Anaesthetic and Surgical Departments at the
1105 Royal Children’s Hospital.

1106

1107 **Data Availability Statement**

1108 The mass spectrometry proteomic data will be deposited to the ProteomeXchange
1109 Consortium via the PRIDE partner repository upon publication. De-identified genomic

1110 data from this study are available for ethically approved research. For queries about the
1111 genomic data sets please contact: david.thorburn@mcri.edu.au.

1112

1113 References

- 1114 1. Haack, T.B. *et al.* Molecular diagnosis in mitochondrial complex I deficiency using
1115 exome sequencing. *J Med Genet* **49**, 277-283 (2012).
- 1116 2. Taylor, R.W. *et al.* Use of whole-exome sequencing to determine the genetic basis of
1117 multiple mitochondrial respiratory chain complex deficiencies. *JAMA* **312**, 68-77
1118 (2014).
- 1119 3. Ohtake, A. *et al.* Diagnosis and molecular basis of mitochondrial respiratory chain
1120 disorders: exome sequencing for disease gene identification. *Biochim Biophys Acta*
1121 **1840**, 1355-1359 (2014).
- 1122 4. Wortmann, S.B., Koolen, D.A., Smeitink, J.A., van den Heuvel, L. & Rodenburg, R.J.
1123 Whole exome sequencing of suspected mitochondrial patients in clinical practice. *J*
1124 *Inherit Metab Dis* **38**, 437-443 (2015).
- 1125 5. Davis, R.L. *et al.* Use of Whole-Genome Sequencing for Mitochondrial Disease
1126 Diagnosis. *Neurology* **99**, e730-e742 (2022).
- 1127 6. Frazier, A.E., Thorburn, D.R. & Compton, A.G. Mitochondrial energy generation
1128 disorders: genes, mechanisms, and clues to pathology. *J Biol Chem* **294**, 5386-5395
1129 (2019).
- 1130 7. Gorman, G.S. *et al.* Mitochondrial diseases. *Nat Rev Dis Primers* **2**, 16080 (2016).
- 1131 8. Skladal, D., Halliday, J. & Thorburn, D.R. Minimum birth prevalence of mitochondrial
1132 respiratory chain disorders in children. *Brain* **126**, 1905-1912 (2003).
- 1133 9. Smeets, H.J.M., Sallevelt, S. & Herbert, M. Reproductive options in mitochondrial
1134 disease. *Handb Clin Neurol* **194**, 207-228 (2023).
- 1135 10. Frazier, A.E., Vincent, A.E., Turnbull, D.M., Thorburn, D.R. & Taylor, R.W.
1136 Assessment of mitochondrial respiratory chain enzymes in cells and tissues.
1137 *Methods Cell Biol* **155**, 121-156 (2020).
- 1138 11. Kremer, L.S. *et al.* Genetic diagnosis of Mendelian disorders via RNA sequencing.
1139 *Nat Commun* **8**, 15824 (2017).
- 1140 12. Yepez, V.A. *et al.* Clinical implementation of RNA sequencing for Mendelian disease
1141 diagnostics. *Genome Med* **14**, 38 (2022).
- 1142 13. Fresard, L. *et al.* Identification of rare-disease genes using blood transcriptome
1143 sequencing and large control cohorts. *Nat Med* **25**, 911-919 (2019).
- 1144 14. Murdock, D.R. *et al.* Transcriptome-directed analysis for Mendelian disease
1145 diagnosis overcomes limitations of conventional genomic testing. *J Clin Invest* **131**
1146 (2021).
- 1147 15. Chen, E. *et al.* Rates and Classification of Variants of Uncertain Significance in
1148 Hereditary Disease Genetic Testing. *JAMA Netw Open* **6**, e2339571 (2023).
- 1149 16. Alston, C.L., Stenton, S.L., Hudson, G., Prokisch, H. & Taylor, R.W. The genetics of
1150 mitochondrial disease: dissecting mitochondrial pathology using multi-omic
1151 pipelines. *J Pathol* **254**, 430-442 (2021).

- 1152 17. Kopajtich, R. *et al.* Integration of proteomics with genomics and transcriptomics
1153 increases the diagnostic rate of Mendelian disorders. *medRxiv*,
1154 2021.2003.2009.21253187 (2021).
- 1155 18. Xiao, Q. & Lauschke, V.M. The prevalence, genetic complexity and population-
1156 specific founder effects of human autosomal recessive disorders. *NPJ Genom Med*
1157 **6**, 41 (2021).
- 1158 19. Sahni, N. *et al.* Widespread macromolecular interaction perturbations in human
1159 genetic disorders. *Cell* **161**, 647-660 (2015).
- 1160 20. Amarasekera, S.S.C. *et al.* Multi-omics identifies large mitoribosomal subunit
1161 instability caused by pathogenic MRPL39 variants as a cause of pediatric onset
1162 mitochondrial disease. *Hum Mol Genet* **32**, 2441-2454 (2023).
- 1163 21. Bakhshalizadeh, S. *et al.* Deficiency of the mitochondrial ribosomal subunit,
1164 MRPL50, causes autosomal recessive syndromic premature ovarian insufficiency.
1165 *Hum Genet* **142**, 879-907 (2023).
- 1166 22. Helman, G. *et al.* Multiomic analysis elucidates Complex I deficiency caused by a
1167 deep intronic variant in NDUFB10. *Hum Mutat* **42**, 19-24 (2021).
- 1168 23. Horvath, R. *et al.* Childhood onset mitochondrial myopathy and lactic acidosis
1169 caused by a stop mutation in the mitochondrial cytochrome c oxidase III gene. *J*
1170 *Med Genet* **39**, 812-816 (2002).
- 1171 24. Van Haute, L. *et al.* TEFM variants impair mitochondrial transcription causing
1172 childhood-onset neurological disease. *Nat Commun* **14**, 1009 (2023).
- 1173 25. Lake, N.J. *et al.* Biallelic Mutations in MRPS34 Lead to Instability of the Small
1174 Mitoribosomal Subunit and Leigh Syndrome. *Am J Hum Genet* **101**, 239-254 (2017).
- 1175 26. Stroud, D.A. *et al.* Accessory subunits are integral for assembly and function of
1176 human mitochondrial complex I. *Nature* **538**, 123-126 (2016).
- 1177 27. Martin, A.R. *et al.* PanelApp crowdsources expert knowledge to establish
1178 consensus diagnostic gene panels. *Nat Genet* **51**, 1560-1565 (2019).
- 1179 28. Rath, S. *et al.* MitoCarta3.0: an updated mitochondrial proteome now with sub-
1180 organelle localization and pathway annotations. *Nucleic Acids Res* **49**, D1541-
1181 D1547 (2021).
- 1182 29. Granata, C. *et al.* High-intensity training induces non-stoichiometric changes in the
1183 mitochondrial proteome of human skeletal muscle without reorganisation of
1184 respiratory chain content. *Nat Commun* **12**, 7056 (2021).
- 1185 30. Thompson, K., Stroud, D.A., Thorburn, D.R. & Taylor, R.W. Investigation of oxidative
1186 phosphorylation activity and complex composition in mitochondrial disease. *Handb*
1187 *Clin Neurol* **194**, 127-139 (2023).
- 1188 31. Bernier, F.P. *et al.* Diagnostic criteria for respiratory chain disorders in adults and
1189 children. *Neurology* **59**, 1406-1411 (2002).
- 1190 32. Acin-Perez, R. *et al.* Respiratory complex III is required to maintain complex I in
1191 mammalian mitochondria. *Mol Cell* **13**, 805-815 (2004).
- 1192 33. Rahman, S. *et al.* Leigh syndrome: clinical features and biochemical and DNA
1193 abnormalities. *Ann Neurol* **39**, 343-351 (1996).
- 1194 34. Tucker, E.J. *et al.* Mutations in MTFMT underlie a human disorder of formylation
1195 causing impaired mitochondrial translation. *Cell Metab* **14**, 428-434 (2011).

- 1196 35. Massa, V. *et al.* Severe infantile encephalomyopathy caused by a mutation in
1197 COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. *Am J Hum Genet* **82**,
1198 1281-1289 (2008).
- 1199 36. Hock, D.H., Robinson, D.R.L. & Stroud, D.A. Blackout in the powerhouse: clinical
1200 phenotypes associated with defects in the assembly of OXPHOS complexes and
1201 the mitoribosome. *Biochem J* **477**, 4085-4132 (2020).
- 1202 37. Zong, S. *et al.* Structure of the intact 14-subunit human cytochrome c oxidase. *Cell*
1203 *Res* (2018).
- 1204 38. Signes, A. & Fernandez-Vizarra, E. Assembly of mammalian oxidative
1205 phosphorylation complexes I-V and supercomplexes. *Essays Biochem* **62**, 255-270
1206 (2018).
- 1207 39. Cizkova, A. *et al.* TMEM70 mutations cause isolated ATP synthase deficiency and
1208 neonatal mitochondrial encephalocardiomyopathy. *Nat Genet* **40**, 1288-1290
1209 (2008).
- 1210 40. Catteruccia, M. *et al.* Persistent pulmonary arterial hypertension in the newborn
1211 (PPHN): a frequent manifestation of TMEM70 defective patients. *Mol Genet Metab*
1212 **111**, 353-359 (2014).
- 1213 41. Torraco, A. *et al.* TMEM70: a mutational hot spot in nuclear ATP synthase deficiency
1214 with a pivotal role in complex V biogenesis. *Neurogenetics* **13**, 375-386 (2012).
- 1215 42. Braczynski, A.K. *et al.* ATP synthase deficiency due to TMEM70 mutation leads to
1216 ultrastructural mitochondrial degeneration and is amenable to treatment. *Biomed*
1217 *Res Int* **2015**, 462592 (2015).
- 1218 43. Magner, M. *et al.* TMEM70 deficiency: long-term outcome of 48 patients. *J Inherit*
1219 *Metab Dis* **38**, 417-426 (2015).
- 1220 44. Sanchez-Caballero, L. *et al.* TMEM70 functions in the assembly of complexes I and
1221 V. *Biochim Biophys Acta Bioenerg* **1861**, 148202 (2020).
- 1222 45. Guerrero-Castillo, S. *et al.* The Assembly Pathway of Mitochondrial Respiratory
1223 Chain Complex I. *Cell Metab* **25**, 128-139 (2017).
- 1224 46. Mowat, D. *et al.* Respiratory chain complex III [correction of complex] in deficiency
1225 with pruritus: a novel vitamin responsive clinical feature. *J Pediatr* **134**, 352-354
1226 (1999).
- 1227 47. Morimoto, M. *et al.* Bi-allelic CCDC47 Variants Cause a Disorder Characterized by
1228 Woolly Hair, Liver Dysfunction, Dysmorphic Features, and Global Developmental
1229 Delay. *Am J Hum Genet* **103**, 794-807 (2018).
- 1230 48. Yang, Q. *et al.* Clinical and genetic analysis of trichohepatoneurodevelopmental
1231 syndrome caused by a CCDC47 variant. *Heliyon* **10**, e27955 (2024).
- 1232 49. Iannello, G. *et al.* Simple, Fast, and Efficient Method for Derivation of Dermal
1233 Fibroblasts From Skin Biopsies. *Curr Protoc* **3**, e714 (2023).
- 1234 50. Amunts, A., Brown, A., Toots, J., Scheres, S.H.W. & Ramakrishnan, V. Ribosome.
1235 The structure of the human mitochondrial ribosome. *Science* **348**, 95-98 (2015).
- 1236 51. Bakker, H.D. *et al.* Human alpha-N-acetylgalactosaminidase (alpha-NAGA)
1237 deficiency: no association with neuroaxonal dystrophy? *Eur J Hum Genet* **9**, 91-96
1238 (2001).

- 1239 52. Sung, A.Y. *et al.* Systematic analysis of NDUFAF6 in complex I assembly and
1240 mitochondrial disease. *Nat Metab* **6**, 1128-1142 (2024).
- 1241 53. Pagliarini, D.J. *et al.* A mitochondrial protein compendium elucidates complex I
1242 disease biology. *Cell* **134**, 112-123 (2008).
- 1243 54. McKenzie, M. *et al.* Mutations in the gene encoding C8orf38 block complex I
1244 assembly by inhibiting production of the mitochondria-encoded subunit ND1. *J Mol*
1245 *Biol* **414**, 413-426 (2011).
- 1246 55. Baide-Mairena, H. *et al.* Mutations in the mitochondrial complex I assembly factor
1247 NDUFAF6 cause isolated bilateral striatal necrosis and progressive dystonia in
1248 childhood. *Mol Genet Metab* **126**, 250-258 (2019).
- 1249 56. Hartmannova, H. *et al.* Acadian variant of Fanconi syndrome is caused by
1250 mitochondrial respiratory chain complex I deficiency due to a non-coding mutation
1251 in complex I assembly factor NDUFAF6. *Hum Mol Genet* **25**, 4062-4079 (2016).
- 1252 57. Kim, J., Lee, J. & Jang, D.H. NDUFAF6-Related Leigh Syndrome Caused by Rare
1253 Pathogenic Variants: A Case Report and the Focused Review of Literature. *Front*
1254 *Pediatr* **10**, 812408 (2022).
- 1255 58. Nguengang Wakap, S. *et al.* Estimating cumulative point prevalence of rare
1256 diseases: analysis of the Orphanet database. *Eur J Hum Genet* **28**, 165-173 (2020).
- 1257 59. Van Bergen, N.J. *et al.* Severe NAD(P)HX Dehydratase (NAXD) Neurometabolic
1258 Syndrome May Present in Adulthood after Mild Head Trauma. *Int J Mol Sci* **24** (2023).
- 1259 60. Tucker, E.J. *et al.* Premature Ovarian Insufficiency in CLPB Deficiency:
1260 Transcriptomic, Proteomic and Phenotypic Insights. *J Clin Endocrinol Metab* **107**,
1261 3328-3340 (2022).
- 1262 61. Van Bergen, N.J. *et al.* Biallelic Variants in PYROXD2 Cause a Severe Infantile
1263 Metabolic Disorder Affecting Mitochondrial Function. *Int J Mol Sci* **23** (2022).
- 1264 62. Frazier, A.E. *et al.* Fatal perinatal mitochondrial cardiac failure caused by recurrent
1265 de novo duplications in the ATAD3 locus. *Med (N Y)* **2**, 49-73 (2021).
- 1266 63. Borna, N.N. *et al.* Mitochondrial ribosomal protein PTCD3 mutations cause
1267 oxidative phosphorylation defects with Leigh syndrome. *Neurogenetics* **20**, 9-25
1268 (2019).
- 1269 64. Van Bergen, N.J. *et al.* Mutations in the exocyst component EXOC2 cause severe
1270 defects in human brain development. *J Exp Med* **217** (2020).
- 1271 65. Lunke, S. *et al.* Integrated multi-omics for rapid rare disease diagnosis on a national
1272 scale. *Nat Med* **29**, 1681-1691 (2023).
- 1273 66. Formosa, L.E., Dibley, M.G., Stroud, D.A. & Ryan, M.T. Building a complex complex:
1274 Assembly of mitochondrial respiratory chain complex I. *Semin Cell Dev Biol* **76**,
1275 154-162 (2018).
- 1276 67. Frederiksen, S.D. *et al.* Rare disorders have many faces: in silico characterization of
1277 rare disorder spectrum. *Orphanet J Rare Dis* **17**, 76 (2022).
- 1278 68. Turner, T.N. *et al.* Proteins linked to autosomal dominant and autosomal recessive
1279 disorders harbor characteristic rare missense mutation distribution patterns. *Hum*
1280 *Mol Genet* **24**, 5995-6002 (2015).
- 1281 69. Dofash, L.N. *et al.* Biallelic variants in *HMGCS1* are a novel cause of
1282 rare rigid spine syndrome. *medRxiv*, 2023.2010.2025.23297129 (2023).

- 1283 70. Gorzynski, J.E. *et al.* Ultrarapid Nanopore Genome Sequencing in a Critical Care
1284 Setting. *N Engl J Med* **386**, 700-702 (2022).
- 1285 71. Australian Genomics Health Alliance Acute Care, F. *et al.* Feasibility of Ultra-Rapid
1286 Exome Sequencing in Critically Ill Infants and Children With Suspected Monogenic
1287 Conditions in the Australian Public Health Care System. *JAMA* **323**, 2503-2511
1288 (2020).
- 1289 72. Dimmock, D. *et al.* Project Baby Bear: Rapid precision care incorporating rWGS in 5
1290 California children's hospitals demonstrates improved clinical outcomes and
1291 reduced costs of care. *Am J Hum Genet* **108**, 1231-1238 (2021).
- 1292 73. Guzman, U.H. *et al.* Ultra-fast label-free quantification and comprehensive
1293 proteome coverage with narrow-window data-independent acquisition. *Nat*
1294 *Biotechnol* (2024).
- 1295 74. Yang, Y. *et al.* Clinical whole-exome sequencing for the diagnosis of mendelian
1296 disorders. *N Engl J Med* **369**, 1502-1511 (2013).
- 1297 75. Akesson, L.S. *et al.* Early diagnosis of Pearson syndrome in neonatal intensive care
1298 following rapid mitochondrial genome sequencing in tandem with exome
1299 sequencing. *Eur J Hum Genet* **27**, 1821-1826 (2019).
- 1300 76. Hoq, M. *et al.* A prospective, cross-sectional study to establish age-specific
1301 reference intervals for neonates and children in the setting of clinical biochemistry,
1302 immunology and haematology: the HAPPI Kids study protocol. *BMJ Open* **9**,
1303 e025897 (2019).
- 1304 77. Robinson, D.R.L. *et al.* Applying Sodium Carbonate Extraction Mass Spectrometry
1305 to Investigate Defects in the Mitochondrial Respiratory Chain. *Front Cell Dev Biol*
1306 **10**, 786268 (2022).
- 1307 78. Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated
1308 proteomic-sample processing applied to copy-number estimation in eukaryotic
1309 cells. *Nat Methods* **11**, 319-324 (2014).
- 1310 79. Bruderer, R. *et al.* Extending the limits of quantitative proteome profiling with data-
1311 independent acquisition and application to acetaminophen-treated three-
1312 dimensional liver microtissues. *Mol Cell Proteomics* **14**, 1400-1410 (2015).
- 1313 80. Tyanova, S. & Cox, J. Perseus: A Bioinformatics Platform for Integrative Analysis of
1314 Proteomics Data in Cancer Research. *Methods Mol Biol* **1711**, 133-148 (2018).
- 1315 81. Hulsen, T. arXiv:2210.04597 (2022).
- 1316 82. Yepez, V.A. *et al.* Detection of aberrant gene expression events in RNA sequencing
1317 data. *Nat Protoc* **16**, 1276-1296 (2021).
- 1318 83. Calvo, S.E. *et al.* Molecular diagnosis of infantile mitochondrial disease with
1319 targeted next-generation sequencing. *Sci Transl Med* **4**, 118ra110 (2012).

1320